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Cohesin is a multiprotein complex essential for cell division and three-dimensional genome 
organisation. Mutations in genes encoding the cohesin-subunits, particularly STAG2, are 
found in ~13% of acute myeloid leukaemia (AML) cases. This frequency is as high as ~50% 
in the Down Syndrome-associated AML subtype (DS-AML). AML is an aggressive form of 
cancer of the bone marrow, with an overall survival rate of less than 30%, with especially 
poor outcomes for older patients. Previous research has shown that cohesin mutations 
dysregulate expression of the leukaemia-associated gene RUNX1. In AML, cohesin mutations 
co-occur with the RUNX1:RUNX1T1 translocation: t(8;21) and with other alterations to 
the RUNX1 gene. Wnt signalling also enhances the spatial proximity 
between RUNX1 and RUNX1T1. 
 
A recent drug screen showed that cohesin-mutant cells were synthetic lethal with Wnt 
agonism (Chin et al., 2020). The increased sensitivity to Wnt was likely due to enhanced β-
catenin stabilisation. Wnt-responsive genes were more sensitized in DS-AML CMK cells 
engineered to contain a patient-specific mutation in cohesin subunit STAG2. This suggests 
that that cohesin mutations could progress oncogenesis by enhancing Wnt signalling, but the 
precise mechanism of this is not known. We hypothesise that Wnt signalling and cohesin 
mutations cooperate to dysregulate Wnt target genes, and possibly increase the frequency of 
the AML translocation: t(8;21). 
 
In this project, we aimed to determine whether cohesin mutations alter β-catenin 
accumulation and/or histone modifications at gene regulatory sites in DS-AML cells. These 
experiments used isogenic DS-AML CMK cells that are unmodified, or that contain a 
CRISPR-generated null mutation in the gene encoding the cohesin subunit STAG2. First, we 
wanted to confirm that CMK cells had stabilised β-catenin in response to Wnt agonism. 
 iii 
Immunofluorescence and cell fractionation followed by immunoblotting showed that the 
Wnt-agonist CHIR99021 enhances β-catenin nuclear accumulation in STAG2 mutant cells. 
Experiments in a second STAG2-edited cell line, MCF10A, confirmed that β-catenin 
accumulation is conserved in STAG2 mutants. 
 
We then used the chromatin immunoprecipitation method CUT&RUN to assess the global 
binding profile of β-catenin in the parental and STAG2 mutant CMK cells stimulated with 
CHIR99021. CUT&RUN with antibodies detecting the histone modifications H3K27ac and 
H3K4me3 was performed to assess whether the chromatin landscape is altered 
in STAG2 mutants at key regulatory sites for RUNX1/RUNX1T1 or other Wnt targets. We 
found increased active histone marks; H3K4me3 and H3K27ac at the P2 promoter 
of RUNX1 and increased H3K27ac at regulatory elements of RUNX1 in STAG2 mutant cells 
upon CHIR99021 treatment. In STAG2 mutants, β-catenin binding to TCF-7 sites was 
enhanced in the inflammatory-response related IL-10 gene which enhances B cell survival, 
proliferation, and antibody production, and the KLHL12 gene, an E3 ubiquitin ligase complex 
that acts as a negative regulator of the Wnt signalling pathway. 
 
We’ve therefore found that STAG2 mutation in addition to Wnt agonism leads to activation 
of enhancers and increased expression of RUNX1 and RUNX1T1 and an alteration of the 
chromatin landscape at each of these genes. 
 
These findings are important, as treatments for AML have not altered significantly in more 
than 30 years and new therapies are urgently needed. Understanding how cohesin mutations 
co-operate with the Wnt pathway can lead to the development of new AML-therapeutics by 
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Chapter 1  Introduction 
1.1 Acute Myeloid Leukaemia (AML)  
Acute Myeloid Leukaemia (AML) is the most common form of myeloid leukaemia, it is a 
disorder characterised by expanded, undifferentiated myeloid precursor cells and impaired 
development of haematopoietic stem cells (HSC) or progenitor cells (HSPC) (Ochi & Ogawa, 
2021). HSCs give rise to all cells of the blood. The ability of all stem cells to carefully 
balance differentiation and regeneration is crucial to their function (Short et al., 2018). In 
AML, HSCs lose the ability to differentiate into mature red cells, neutrophils, monocytes, and 
platelets, and no longer respond correctly to growth signals (Döhner et al., 2015) such that 
they have enhanced proliferation capacity. This means there is an incorrect makeup of cells in 
the blood which can lead to infection, bleeding, organ and bone marrow failure, and death 
(Estey & Döhner, 2006). AML diagnosis is characterised by clonal expansion of 
undifferentiated myeloid precursors, resulting in impaired haematopoiesis and bone marrow 
failure (Ferrara & Schiffer, 2013). AML may develop through several different genetic 
mutations (Short et al., 2018; Heimbruch et al., 2021). For the purposes of this thesis, I will 
focus on the genetic pathogenesis of this disease.  
1.1.1 Mutational Landscape of AML 
 
Large scale AML genome and exome sequencing identified recurrently mutated genes that 
are causative for this disease. Papaemmanuil et al., 2016 found 5234 driver mutations across 
76 genes or genomic regions. They identified 11 classes based on co-mutation and 3 genomic 
categories of gene mutations in AML which are as follows: AML with mutations in genes 
encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 
mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with 
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IDH2R172 mutations (in 1%) (Papaemmanuil et al., 2016). Genes encoding members of the 
cohesin complex; RAD21, SMC3, SMC1A and STAG2 were frequently mutated and 
implicated in AML as chromatin-spliceosome mutations. (Cancer Genome Atlas Research 
Network et al., 2013; Papaemmanuil et al., 2016). Cancer develops from somatically acquired 
driver mutations and thus it makes sense to categorise cancer by causative genomic changes 
rather than morphological ones (Papaemmanuil et al., 2016). In myeloid malignancies, 
cohesin mutations occur in 10%–12% of AML cases (Kon et al., 2013) and the frequency of 
cohesin mutations in Down syndrome-associated megakaryoblastic leukaemia (DS-AMKL) 
is even higher (∼50%) (Yoshida et al., 2013). Cohesin insufficiency stops the differentiation 
of haematopoietic stem cells (HSCs) and reinforces the stem cell transcriptional program. 
(Mazumdar et al., 2015; Viny et al., 2015; Mullenders et al., 2015). The gene encoding the 
STAG2 subunit of cohesin is the most frequently mutated cohesin gene in myeloid 
malignancies (Kon et al., 2013). Mutations in STAG2 are hemizygous and partially 
compensated for by STAG1 (Smith et al., 2020). Mutations in cohesin are placed into a 
category called chromatin-spliceosome that are cancer drivers in AML (Papaemmanuil et al., 
2016). AML with this category of mutation has a very poor prognosis (Ochi & Ogawa, 
2021). Haematopoietic cells with chromatin-spliceosome mutations have incorrect 3D 
genome organisation and thus aberrant gene expression often of genes that contribute to 
leukemogenesis (Ochi & Ogawa, 2021).  
 
1.2 Cohesin 
1.2.1 Cohesin structure and dynamics 
Cohesin is made up of four core subunits RAD21, SMC3, SMC1A and STAG1/2 that form a 
ring-shaped structure to entrap DNA (Figure 1.1) (Nasmyth & Haering, 2009). SMC1A and 
SMC3 dimerise to a hinge region and RAD21 connects these two at their ATPase domain 
 3 
which forms the characteristic ring (Dorsett, 2009). Either STAG1 or STAG2 bind to RAD21 
completing the cohesin ring (Nasmyth & Haering, 2009). Importantly, cohesin mutations 
result in haploinsufficiency or insufficiency because complete loss would prevent cell 
division (Fisher et al., 2017; Leeke et al., 2014). However, STAG2 and SMC1A are on the X 
chromosome, and mutations in these subunits are tolerated because of compensation by their 
counterparts, STAG1 and SMC1B (meiotic) respectively (van der Lelij et al., 2020). Cohesin 
is loaded onto chromatin through the combined mechanisms of two different groups of 
proteins (Antony et al., 2021). Cohesin associates with chromatin in the G1 phase of the cell 
cycle requiring the presence of the NIPBL–MAU2 heterodimer and ATP hydrolysis (Figure 
1.1). For unloading, two factors - WAPL and PDS5 - associate with each other and with 
chromatin-bound cohesin and promote cohesin unloading (Figure 1.1) (Wutz et al., 2017). 
Therefore, the fraction of cohesin that is present on chromatin is the result of the opposing 
actions of NIPBL–MAU2 and PDS5–WAPL (Losada, 2014). The amount of cohesin on 
chromatin is balanced by these 
loading and unloading processes 
and is essential for correct 
chromosome structure and 
function (Antony et al., 2021). 
Cohesin and similar orthologues 
have been conserved in structure 
over multiple lineages through 
multiple generations (Koninck & 
Losada, 2016) which suggests it 
has extremely integral functions 
in the cell.  
Figure 1.1 Overview of the cohesin complex and its associated proteins. SMC1, 
SMC3, RAD21, and SA(STAG1/2) are part of the cohesin subunit. Other proteins 
regulate cohesins binding to DNA and its residency there. The NIPBL/MAU2 dimer 
loads cohesin onto DNA, whereas WAPL/PDS5 release cohesin from chromosomes 
by opening the SMC3-RAD21 interface. Created with BioRender.com 2021.  
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1.2.2 Cohesin functions 
 
Cohesin was first discovered for its role in sister chromatid cohesion during mitosis 
(Michaelis et al., 1997). Cohesin has several functions within the cell. The best known is its 
function during mitosis in sister chromatid cohesion, kinetochore orientation and spindle 
assembly (Nasmyth & Haering, 2009). In addition, cohesin is involved in DNA damage 
repair (Sjögren & Nasmyth, 2001; Kim et al., 2002; Ström et al., 2004; Nishiyama, 2019). 
Only a small percentage (13%) of cohesin is used for such cell cycle functions (Gerlich et al., 
2006; Heidinger-Pauli et al., 2010), so what does the rest of it do? A significant proportion of 
cohesin is involved in genome organisation and control of transcription (Wendt et al., 2008; 
Liu et al., 2009; Dorsett, 2010; Nishiyama, 2019). The compaction of DNA into higher order 
structures has important implications for transcriptional regulation. Such structures allow 
interactions of enhancers and promoters across extremely broad ranges. Cohesin can encircle 
DNA and extrude it to form loops further controlled by chromatin bound CTCF (Bauer et al., 
2021), forming what is known as topologically associated domains (TADs) (Merkenschlager 
& Nora, 2016). TADs are highly interactive sections of looped DNA; they contain 
neighbourhoods of genes subjected to regulation through the same regulatory elements (such 
as ‘enhancers’) present in the TAD (Fang et al., 2020). While it is known cohesin forms intra-
TAD loops connecting genes to enhancers, this loop formation must occur through 
association with the CCCTC-binding factor (CTCF) insulator protein at TAD boundaries to 
shield genes from enhancers in other TADs. These loops and boundaries can be repressive or 
active (Hnisz et al., 2016). Cohesin regulatory proteins NIPBL, WAPL, MAU2 and PDS5 
(Figure 1.1) are equally necessary for correct loop extrusion and chromatin organisation 
(Mazzola et al., 2019). STAG1 and STAG2 subunits of cohesin have redundant and non-
redundant roles in chromatin organisation and gene expression (Kojic et al., 2018; Cuadrado 
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& Losada, 2020). Both orthologues co-localise with CTCF and have common and 
independent genomic binding sites. STAG1 stabilises TAD boundaries and disrupts long 
range PRC1 interactions, which disrupts correct compartmentalisation. STAG2 facilitates 
local enhancer-promoter interactions and long range Polycomb repressive complex 1 (PRC1) 
interactions necessary for gene repression (Kojic et al., 2018). Mutations in genes encoding 
for proteins that help modulate such structures are essential for controlling the formation of 
TADs and creating transcription boundaries within chromatin. Importantly in the case of 
AML, the cohesin complex and the insulator binding protein CTCF, as well as regulatory 
proteins are necessary for correct gene expression. Therefore, cohesin is essential for proper 
enhancer-promoter connectivity that underpins transcriptional programs in development and 
cancer (Rao et al., 2017).  
 
1.2.3 Cohesin mutations in cancer 
 
Barber et al., 2008 were the first to show that mutations in cohesin subunits are related to 
oncogenesis. They found missense mutations in SMC3, SMC1A and NIPBL in colorectal 
cancer cell samples. Cohesin is essential for cell viability, but partial loss-of-function 
mutations can affect genome organisation processes (Koninck & Losada, 2016). STAG2 is 
one of only 12 genes that are significantly mutated in four or more major human 
malignancies (Lawrence et al., 2014) It is interesting to note here, that there is a synthetic 
lethal interaction between STAG2 and its paralogue STAG1 (Benedetti et al., 2017). Loss-of-
function of STAG2 leads to synthetic dependency of mutated cancer cells on its paralog 
STAG1 which provides evidence STAG1 may be an interesting therapeutic target (Benedetti 
et al., 2017). STAG2 loss of function mutations that drive tumorigenesis are well researched, 
the pathological mechanism is thought not to be related to issues with chromatid cohesion 
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and aneuploidy, but rather that these mutations interfere with cohesins role in gene regulation 
and genome organisation (Koninck & Losada, 2016; Waldman, 2020). Cohesin mutations are 
known to contribute to human cancer, particularly in bladder cancer, Ewing sarcoma and 
myeloid malignancies (Hill et al., 2016). Most commonly mutations that cause these cancers 
are in the STAG2 subunit (Romero-Pérez et al., 2019). These are often loss-of-function due to 
the typically truncating effect of such mutations, resulting in a non-functional protein. Hill et 
al., 2016 thus states that it is appropriate to classify STAG2 as a tumour suppressor gene.  
 
1.2.4 Cohesin mutations in myeloid malignancies 
 
In AML the mutation frequency of cohesin is as high as 13% in all cases (Kon et al., 2013; 
Thota et al., 2014; Fisher et al., 2017; Cuartero et al., 2019; Han et al., 2021). Normal 
haematopoiesis is controlled by regulatory transcription factors that coordinate the balance 
between haematopoietic stem/progenitor cell self-renewal and lineage commitment, but in 
AML there is increased self-renewal and impaired differentiation which is often related to 
altered transcription (Viny et al., 2015). Interestingly there is also a high association between 
cohesin mutations and Down Syndrome acute megakaryoblastic leukaemia (DS-AMKL) 
found by Yoshida et al., 2013. 53% of all DS-AMKL samples had mutations either in cohesin 
or regulatory proteins of cohesin which were mutually exclusive (Yoshida et al., 2013).  
However, the question remains – how do cohesin mutations cause cancer? When the first 
studies on cohesin gene mutations in association with cancer came out, it was suggested that 
the mutations were causing chromosomal instability and aneuploidy (Solomon et al., 2011). 
This was supported by initial studies on cohesin in yeast and other model organisms 
describing its canonical role in sister chromatid cohesion (Zhang et al., 2008). However, later 
research identified that many myeloid tumour cells with cohesin mutations showed a normal 
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karyotype (Thota et al., 2014), so instead it was proposed that reduced cohesin function alters 
chromatin structure and disrupts gene regulation in haematopoietic progenitor cells triggering 
leukaemogenesis (Viny & Levine, 2018).  
 
1.2.5 Cohesin mutant AML transcriptional profile 
 
Many studies looking at cohesin mutations tried to show the phenotypic consequences of 
cohesin mutations on leukaemia, with little success, so the focus was moved to look at 
transcriptional consequences. Mazumdar et al., 2015 transduced HSCs with mutant SMC1A, 
SMC3, RAD21 and STAG2 constructs and they saw reduced haematopoietic differentiation 
and an increase in haematopoietic stem and progenitor cells (HSPCs). At a molecular level, 
differentially expressed genes in mutant cohesin expressing HSPCs were identified that 
included upregulation of genes important for maintenance of HSCs and downregulation of 
genes required for differentiation. Cohesin mutant cells showed a global reduction of 
chromatin accessibility at transcription start sites, but some showed an increased level of 
chromatin accessibility. Work by Mazumdar et al., 2015; Mullenders et al., 2015; Viny et al., 
2018 has also shown that cohesin mutation causes a change in chromatin accessibility which 
has important consequences for transcription. ATAC-seq performed by Mazumdar et al., 
2015 showed an increased level of chromatin accessibility at genes encoding the ERG, 
GATA2 and RUNX1 transcription factors. Galeev et al., 2016 found through a genome wide 
RNAi screen, that STAG2, RAD21, STAG1, and SMC3 (cohesin genes) were among the top 
20 genes from the screen. Upon individual validation of these cohesin genes, Galeev et al., 
2016 found that their knockdown led to an immediate expansion of cells with an HSC 
phenotype in vitro. Viny et al., 2019 also showed that STAG2 deletion in HSCs increased 
self-renewal and impaired differentiation. They performed ChIP-seq and revealed that 
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STAG1/2 bind shared loci, but a number of STAG2 binding sites are not occupied by STAG1 
even when STAG2 is knocked down. They found loss of STAG1/2 alters haematopoiesis, but 
loss of STAG2 alone decreased chromatin accessibility and thus transcription of lineage-
specific genes – Ebf1 and Pax5 - inducing self-renewal and stopping cell fate commitment of 
these cells. This research showed distinct roles for STAG1/2 in chromatin accessibility and 
topological control of HSC self-renewal and differentiation. Mazumdar et al., 2015 also 
showed that knockdowns of GATA2 or RUNX1 revert the differentiation block induced by 
cohesin deficiencies, which further supports their idea that the stem cell transcriptional 
profile and phenotype was triggered by dysregulation of these haematopoietic transcription 




RUNX1 is an important transcription factor necessary for the development of leukaemia stem 
cells (LSCs) (Wesely et al., 2020). RUNX1 has an important association with AML due to a 
loss of function – as a partner of fusion genes generated by translocation or germline/somatic 
mutations (Wesely et al., 2020). But on a molecular level it is poorly understood how this 
occurs – especially when cohesin mutations come into play. Gerritsen et al., 2019 found that 
RUNX1 mutations enhance self-renewal and block differentiation of induced pluripotent stem 
cells (iPSCs). RUNX1 expression is altered - either through loss of function mutations or 
translocations - in many myeloid disorders due to its role in sustaining stem-cell phenotype 
(Wesely et al., 2020). RUNX1 is under the control of two different promoters. The distal P1 
and proximal P2 which give transcripts that differ in the 5’ untranslated regions and N-
terminal coding sequences (Sroczynska et al., 2009). At full length they produce RUNX1c 
and RUNX1b isoforms respectively (Figure 1.2). A further level of control is through 
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alternative splicing of either the proximal or distal transcript to generate further isoforms the 
production of these transcripts change through different stages of development and 
differentiation of haematopoietic cells (Sroczynska et al., 2009).  
 
In AML, RUNX1 is commonly altered through mutations or translocation, and these are well 
researched, an equally important but less well researched area is how mutations in RUNX1 
regulatory elements affect expression of the gene. Horsfield et al., 2007 identified that 
cohesin subunit RAD21 is a positive regulator of runx1 in zebrafish, and that RAD21 mutant 
zebrafish embryos lose expression of lateral plate mesoderm runx1 expression in cells that 
will later go on to become blood. A later paper by Marsman et al., 2014 discovered CTCF 
and cohesin binding sites both inside and outside of the RUNX1 gene, and that depletion of 
cohesin enhances expression of RUNX1 in a human haematopoietic cell line. Further research 
on this subject by Marsman et al., 2017 focused on regulatory elements upstream of P1 and 
P2 and how these may contact the mouse Runx1 promoters. They revealed an interaction 
between the +24 Runx1 enhancer, which contacts promoters of Runx1 in both mouse and 
leukaemia cell lines. The results showed that the +24 enhancer interacts within a 1.1 Mb long 
topologically associating domain (TAD) comprising the complete RUNX1 gene as well as 
Figure 1.2 Schematic representation of the human RUNX1 isoforms (Marshall et al., 2008). Boxes in the RUNX genes 
represent exons, open boxes represent noncoding exons, and shaded boxes indicate coding exons. The dual promoters (Distal  
(P1) and Proximal (P2)), Runt domain, and transcriptional transactivation domains are shown. The three major splice variants 
(1a, 1b and 1c) of RUNX1 are indicated. The exon (boxes) are numbered according to the UCSC Genome browser annotations 
and the 3  ́and 5  ́untranslated regions (UTRs )are shown as white boxes. The Runx1a and Runx1b isoforms are transcribed from 




with loci outside of this. They discovered that there is essentially a local ‘active chromatin 
hub’ that in haematopoietic cells controls RUNX1 expression (Marsman et al., 2017).  
There is also an important interaction between STAG2 and RUNX1 controlling enhancer-
promoter looping and transcription. Ochi et al., 2020 found that loss of STAG2 and RUNX1 
which both congregate at CTCF deficient and enhancer rich sites stops correct formation of 
enhancer-promoter loops and dysregulates RUNX1 expression. Further on from this, it has 
been found that STAG2 loss alters inducible RUNX1 expression in megakaryocytes (Antony 
et al., 2020). Cohesin is required for inducible enhancer activity that underpins inflammatory 
gene expression (Cuartero et al., 2018). This finding is consistent with the role of 
inflammatory signals in promoting myeloid differentiation of HPSCs. Cuartero et al., 2018’s 
findings uncover an unexpected dependence of inducible gene expression on cohesin. Antony 
et al., 2020 found that STAG2 depletion de-constrains the chromatin surrounding RUNX1 and 
ERG, which causes aberrant enhancer-amplified transcription in response to differentiation 
signals, leading to the idea that cohesin loss and transcriptional changes became important 
upon signals. What is interesting to note however is that increases in RUNX1 expression have 
not only been found in cohesin mutants but also when Wnt stimulation is present (Ugarte et 
al., 2015).  
 
1.3 Wnt Signalling 
1.3.1 Wnt signalling pathway 
The Wnt signalling pathway acts through two cell surface receptors, Fz (frizzled) – a 
transmembrane receptor that binds directly to Wnt – and a co-receptor, LRP, which 
associates with Fz and Wnt (Figure 1.3). Wnt essentially controls the balance between the 
three pools of β-catenin involved in cytoskeletal ligatures, cytosolic complex (for destruction) 
and nuclear pool which drives transcription (Kolligs et al., 2002). If Wnt or any member of 
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the signal transduction pathway is mutated this can cause numerous problems including 
cancer. In the absence of Wnt (- Wnt, Figure 1.3) the Fz and LRP receptor and co-receptor 
respectively exist, but with no ligand bound. In the nucleus there are target gene/s which are 
repressed by Gro (Groucho) bound to TCF. In the cytoplasm there exists a complex of Axin 
(scaffold protein) and APC with β-catenin. To these proteins GSK-3 and CK1 are also bound. 
Axin mediates the formation of this complex by facilitating the phosphorylation of β- catenin 
by GSK-3 and CK1. When β-catenin is phosphorylated by CK1 and GSK-3 this allows TrCP 
to bind the complex, ubiquitinylate β-catenin and target it for proteasomal destruction. This 
means β-catenin cannot translocate into the nucleus and act as a transcription activator, thus 
the target genes stay repressed (MacDonald et al., 2009). In the presence of Wnt (+ Wnt 
Figure 1.3) Wnt binds to the LRP and Fz receptors. This binding allows the LRP co-receptor 
to be phosphorylated. This then recruits two proteins; Axin which then binds dishevelled 
(DVL). Axin is now sequestered and there is no complex of proteins as seen when Wnt is not 
present. β-catenin is thus not phosphorylated by CK1 and GSK-3 and it can accumulate in the 
Figure 1.3 The Wnt/β-catenin signalling pathway (Suryawanshi et al., 2016). The left of the Figure shows the pathway 
and proteins active in the absence of Wnt and the right of the Figure shows the pathway and proteins active in the presence 
of Wnt.  Refer to main text for further details 
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cell as it is not targeted for destruction. β-catenin can then translocate into the nucleus where 
it interacts with TCF, which removes the Gro repressor and allows β-catenin to recruit 
transcription activators (Gruszka et al., 2019) (Figure 1.3). Following Wnt activation, 
phosphorylation of β-catenin at S675 by protein kinase A (PKA) and at S552 by AKT also 
facilitates to stabilize β-catenin for nuclear translocation (Fang et al., 2007). 
1.3.2 E-cadherin/β-catenin and the epithelial barrier 
Cell-cell junctions are required to maintain cell and tissue polarity and integrity. Epithelial 
cells bind together through the homophilic binding of E-cadherins, which form an 
intracellular molecular complex with several molecules, such as β-catenin and actin filaments 
(Yang & Kim, 2014). The E-cadherin/β-catenin complex (Figure 1.3: -Wnt) plays an 
important role in maintaining epithelial integrity. The disruption of this complex affects not 
only the adhesive properties of a cell, but also the Wnt-signalling pathway. Aberrant 
expression of this complex has been shown to be associated with a wide variety of human 
malignancies and disorders of fibrosis resulting from epithelial-mesenchymal transition (Tian 
et al., 2011). 
 
1.3.3 β-catenin phosphorylation 
 
An important level of control of the Wnt/β-catenin pathway is the regulation of degradation 
of β-catenin through its phosphorylation. APC, Axin and GSK-3 make up what is known as 
the ‘destruction complex’ that controls degradation of β-catenin. Three conserved Ser/Thr 
residues present on the amino-terminal of β-catenin - serine 33 and 37 and threonine 41- are 
the targets of active serine kinase GSK-3 (Noort et al., 2002). GSK-3 is a Ser/Thr kinase with 
a vital role in the Wnt/β-catenin signalling pathway (Huang et al., 2017). However, GSK-3 is 
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not the only component of phosphorylation that occurs in this pathway. Liu et al., 2002 found 
another Axin-associated kinase which precedes and is required for GSK-3 phosphorylation. 
This complex is casein kinase Iα (CKIα) and 
phosphorylates β-catenin at S45 in vivo (Figure 
1.4). When a cell is not receiving Wnt 
stimulation, GSK-3 and CKIα phosphorylate β-
catenin, which triggers β-catenin recruitment of 
ubiquitin E3 Ligase β-TrCP causing its 
ubiquitination and targeting it for proteasomal 
degradation (Gao et al., 2014). When Wnt 
signalling is present, CKIα & GSK-3’s kinase 
activity is inhibited, so β-catenin is not targeted 
to the proteasome and is not degraded (Gao et al., 
2014). It can then travel to the nucleus and 
complex with LCF/LEF factors.  
 
A potential determinant of the structural integrity of the E-cadherin/β-catenin complex (1.3.2) 
may depend on its phosphorylation status. Phosphorylation of E-cadherin or β-catenin by 
Ser/Thr kinase CK II stabilizes the complex (Lickert et al., 2000). However, tyrosine 654 
phosphorylation of β-catenin by an intracellular signalling event disrupts the E-cadherin/β-
catenin complex and cell adhesion (Behrens et al., 1993). The phosphorylation of β-catenin at 
tyrosine 489 or 142 enhances Wnt signalling (Rhee et al., 2007). Tyrosine phosphorylation 
can release β-catenin from E-cadherin, decrease cell-cell junction adhesion, and increase cell 
migration and invasiveness (Hülsken et al., 1994). 
 
Figure 1.4 A model for β-catenin phosphorylation and 
recognition. CKIα, GSK-3, and β-catenin each bind a 
different domain of Axin such that CKIα and GSK-3 
sandwich β-catenin in the Axin complex. CKIα 
phosphorylation of S45 allows GSK-3 to phosphorylate 
T41, then S37 and S33. Phosphorylation of S37 and S33 
creates the recognition site for β-Trcp. Wnt signalling 
inhibits GSK- 3 phosphorylation of T41, S37, and S33. 
(Created using GoodNotes 2021)  
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A lot is known about GSK-3 phosphorylation control – it has been found that inhibition of 
GSK-3 activity such as with LY2090314 (Atkinson et al., 2015) can lead to stabilisation and 
activation of β-catenin and TCF/LEF-dependent gene transcription, which reflects the activity 
of Wnt signal transduction (Huang et al., 2017). However an area of interest to work on is 
how CKIα phosphorylation is regulated as this currently remains largely unknown.  
 
1.3.3 Wnt/β-catenin and AML 
 
The Wnt/β-catenin pathway is both extremely well characterised and conserved, and its 
association with cancer is well documented (Frenquelli & Tonon, 2020). Studies looking at 
the Wnt/β-catenin pathway in stem cells and cancer stem cells have shown that Wnt is crucial 
for maintaining stem cell function and inhibiting differentiation (Jackstadt et al., 2020). 
Activation of Wnt signalling during haematopoiesis is crucial for blood development (Lento 
et al., 2013). However, constitutively active β-catenin due to excessive Wnt signalling, 
inhibition of GSK-3 (Erbilgin et al., 2012) and other mechanisms, leads to excessive stem 
cell renewal predisposing cells to tumorigenesis. In addition to numerous other cancers, 
increased Wnt signalling is also found in AML (Staal et al., 2016) and this was found through 
a number of gain-of-function and loss-of function studies. Gain-of-function (GOF) studies 
showed that the addition of WNT3A and inhibition of GSK-3 both activate β-catenin and 
promote proliferation of committed haematopoietic progenitors in human embryonic stem 
cells (Lento et al., 2013). Loss-of-function (LOF) studies deleting either β-catenin or 
components of the Wnt pathway have shown a severe reduction in the amount of HSC and 
HSPCs – often being lethal (Lento et al., 2013). AML cells depend on the Wnt/β-catenin 
pathway for initiation of tumorigenesis and growth and, in some cases, resistance to therapies 
(Perry et al., 2020). Interestingly Müller-Tidow et al., 2004 also found that AML associated 
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translation products – such as the RUNX1-RUNX1T1 (t(8;21)) translocation – can induce 
TCF/LEF signalling (a downstream product of Wnt signalling). 
 
1.4 Cohesin, chromosomal translocations, Wnt signalling and AML 
1.4.1 Chromosomal translocations 
Karyotype analysis of a sample of AML patients revealed that there were chromosome 
aberrations in more than 75% of patients (Palanisamy, 2010). One of the most common was 
the t(8;21) (q22;q22) translocation. This involves a fusion between the RUNX1 gene (also 
known as AML1) on chromosome 21 and the RUNX1T1 (also known as ETO) gene on 
chromosome 8 (Figure 1.5) and occurs in between 5-12% of all AML cases (Palanisamy, 
2010). RUNX1-RUNX1T1 leukaemia is said to be the most common cytogenetic subtype of 
acute myeloid leukaemia (Lin et al., 2017). The resultant fusion product is a leukaemia-
initiating transcription factor that hinders RUNX1 function (Lam & Zhang, 2012). The result 
of this interference is a block in differentiation and, ultimately, the development of AML 
(Ptasinska et al., 2012). Mechanisms that drive this translocation had been unclear for a while 
until Ugarte et al., 2015 published their work. The first studies to show a role for Wnt in 
Figure 1.5 Genomic structure of AML1 (RUNX1) on chromosome 21 and ETO (RUNX1T1) on chromosome 8. 
Exons are shown as white/blue boxes. RUNX1 is shown on chromosome 21 and RUNX1T1 is shown on chromosome 
8. Wnt/β-catenin was shown to induce spatial proximity and translocation of RUNX1 and RUNX1T1, which led to the 
generation of the RUNX1-RUNX1T1 fusion gene (Lin et al., 2017)  
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AML showed that fusion genes – such as RUNX1-RUNX1T1 activated γ-catenin (a 
homologue of β-catenin) as well as increasing Wnt signalling (Müller-Tidow et al., 2004). 
Using expression microarray analysis Steffen et al., 2011 also showed that the Groucho 
inhibitory protein AES, was a significantly upregulated RUNX1-RUNX1T1 target, further 
elucidating the idea that RUNX1/RUNX1T1 is involved with Wnt signalling.  
 
1.4.2 Cohesin mutations, translocations and Wnt signalling 
 
Ugarte et al., 2015 found that stimulating cells with WNT3A – inducing the Wnt/β-catenin 
pathway – increases the expression of RUNX1T1 and RUNX1 genes and also, interestingly, 
brings both the RUNX1T1 and RUNX1 genes into close spacial proximity (Figure 5). 
Following on from this, long-term treatment of human haematopoietic progenitors with 
WNT3A induced the RUNX1-RUNX1T1 translocation (Ugarte et al., 2015). This paper 
ultimately uncovered that Wnt/β-catenin signalling both induces transcription and 
translocation of RUNX1 and RUNX1T1. To understand the role of Wnt/β-catenin signalling in 
other recurrent translocations of AML should be a goal of further investigations. As 
described above, RUNX1 has two promoter regions that regulate its expression: the distal P1 
and proximal P2. Initiation of the Wnt/β-catenin has been shown to produce the longer distal 
P1-RUNX1 mRNA (Medina et al., 2016). Experiments from Medina et al., 2016 also showed 
through GOF and LOF experiments that RUNX1-P1 expression occurs through a β-catenin-
responsive region with a TCF/LEF binding element upstream of the P1 promoter. They 
therefore concluded that the P1 promoter is a direct target of Wnt/β-catenin signalling that 
may be important in leukaemogenesis. An interesting paper by Chin et al., 2020 showed that 
cohesin mutant cells were sensitive to LY2090314, a GSK-3 inhibitor and agonist of Wnt 
signalling. They presume that sensitivity to GSK-3 inhibition is likely due to stabilisation of 
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β-catenin in cohesin-mutant cells. Chin et al., 2020 also showed that Wnt-responsive gene 
expression is highly sensitized in STAG2-mutant CMK leukaemia cells, and further, that Wnt 
activity is enhanced in zebrafish mutant for cohesin subunits stag2b and rad21. These results 
suggest that cohesin mutations could progress oncogenesis by enhancing Wnt signalling. It is 
well documented that cohesin mutations co-occur with AML, even in up to 20% of cases 
(Heimbruch et al., 2021), and that it is not in the role of cohesin in sister chromatid cohesion 
where cohesin mutations make a difference but it is rather cohesins role in controlling DNA 
looping and gene expression which leads to leukaemogenesis (Heimbruch et al., 2021). 
However the mechanism of transformation from HSC to a leukaemia cell is not necessarily a 
simple process and we need to think about the environment in which the stem cell resides. It 
is known that aberrant Wnt signalling is observed inside the bone marrow and can induce 
AML (Frenquelli & Tonon, 2020). It is also known that there is disruption to 3D chromatin 
organisation with increased chromatin accessibility at transcription factor binding sites for 
RUNX1, which is also a Wnt target gene, in cohesin mutant cells (Mazumdar et al., 2015). It 
is possible that already dysregulated transcription due to cohesin mutations may be further 
disrupted by aberrant Wnt signalling as Chin et al., 2020 proposed.  
 
1.5  Aims and Hypothesis  
 
Taking previous research into account, I hypothesise that cohesin mutations cooperate with 
Wnt signalling to dysregulate transcriptional changes by altering the chromatin landscape and 
downstream β-catenin-TCF-7 signalling events.  
 
The outcome of this research is to identify whether regulatory regions associated with break 
points or oncogenic genes have differential chromatin upon Wnt activation in cohesin mutant 
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cells. Wnt signalling is an important developmental control that contributes to cancer 
development. Understanding how cohesin mutations co-operate with this pathway is 
important for the development of therapeutics.  
 
The overall aim of the project is to determine how cohesin mutations increase sensitivity to 
Wnt signalling. I am investigating whether loss of cohesin would lead to chromatin landscape 
changes and aberrant accumulation of β-catenin and TCF-7 at regulatory sites of RUNX1 and 
RUNX1T1 upon Wnt stimulation.  
To achieve this, I carried out the following experimental objectives:  
1. Validate whether WNT agonist CHIR99021 has the same efficacy as WNT3A in 
parental and cohesin-STAG2 mutant isogenic Down syndrome megakaryoblastic 
CMK leukaemia cells. 
2. Use the chromatin immunoprecipitation method, CUT&RUN, to determine whether 
the chromatin landscape and β-catenin/TCF-7 binding sites are altered with Wnt 







Chapter 2  Methods and Materials  
2.1  Chemicals and solutions  
All chemicals were of analytical grade. Solutions are listed in (6). Solutions and dilutions 
were prepared using deionised MilliHQTM water (Millipore Corporation) – here named MQ 
water – or UltraPureTM DNase/RNaseHFree Distilled Water (LifeTechnologies) – here named 
UltraPureTM water. 
2.2  Cell Culture Techniques 
2.2.1 CMK and MCF10A cohesin-deficient isogenic cell lines  
CMK is an acute megakaryoblastic leukaemia cell line that has erythroid and myeloid 
markers. Parental CMK was originally stablished from a Down's syndrome patient suffering 
from acute megakaryoblastic leukaemia (Sato et al., 1989). Cohesin-deficient isogenic CMK 
cell lines were generated in the Horsfield lab previously using CRISPR-Cas9 to contain the 
R614* null mutation in the STAG2 subunit of cohesin (Chin et al., 2020). CMK cells are 
megakaryocytic with a tetraploid genome. This clone is may also be known as STAG2-/y but 
will hereafter be referred to as STAG2-/- to denote that it has no functional STAG2. 
Parental MCF10A is a non-tumorigenic, epithelial cell line derived from normal breast 
epithelium. The MCF10A cell line was sourced from ATCC (ATCC® CRL-10317TM). 
Cohesin-deficient isogenic MCF10A cell lines were previously generated in the Horsfield lab 
using CRISPR-Cas9 to introduce deletion null mutation in the STAG2 subunit of cohesin. 
All main experiments were carried out in the isogenic CMK lines and MCF10A lines were 
used as validation for β-catenin expression analyses.  
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2.2.2 Maintenance and subculture of CMK cells  
CMK parental and cohesin-deficient (STAG2-/-) cell lines were maintained in growth 
medium composed of RPMI (RPMI 1640) supplemented with Glutamax and 10% FBS. Cells 
were cultured in a 37 oC/5 % CO2 incubator. Cells were grown in Cellstar® 50ml Filter Cap 
Cell Culture Flask (Greiner Bio-One.) Cells were grown to 75-80% confluency and 
maintained through subculturing. CMK cells are slightly adherent. For subculture, suspension 
cells were first transferred to a falcon tube, PBS was then added to wash the adherent cells, 
following which 0.05% trypsin was added to the culture dish. Following a brief incubation 
(approximately 3 minutes), media was added to neutralize the cells and the trypsinised cells 
were transferred to the falcon containing suspension cells. Cells were centrifuged at 250 g for 
3 minutes and cell pellets were resuspended in 10 ml fresh media. Cells were sub-cultured at 
a 1:5 or 1:10 ratio. For seeding cells for immunofluorescence, immunoblotting and treatment 
experiments, viable cells were counted using 10 μl of 0.4% trypan blue solution added to 10 
μl of cell suspension, 5 μl of the mixture was placed in a Cell Counting Slide (Luna™) and 
counted by the Luna II ™ Automated Cell Counter and seeded as required.  
2.2.3 Maintenance and subculture of MCF10A cells  
MCF10A parental and cohesin-deficient (STAG2-/-) cell lines were maintained in growth 
medium composing of Dulbecco’s modified Eagle medium (DMEM) culture medium 
supplemented with 5% horse serum, 20 ng/ml of epidermal growth factor (EGF), 0.5 mg/ml 
of hydrocortisone, 100 ng/ml of cholera toxin and 10 μg/ml of insulin. Cells were cultured in 
a 37 oC/ 5 % CO2 incubator. MCF10A cells were grown to 75-85% confluence (log phase). 
To subculture cells, spent cell culture media was removed, and cells were washed with PBS 
(Gibco). 0.05 % trypsin/EDTA was added into flask (just enough reagent to cover the cell 
layer) to detach cells from the flask surface and left for 20 minutes in a 37 oC/ 5 % CO2 
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incubator. When more than 90% of the cells have detached, growth medium was added to 
neutralize the trypsin. Cells were transferred into a 15 ml falcon tube and centrifuged at 250  
g for 5 minutes.  Cells were sub-cultured using a 1:5 or 1:10 ratio and counted for 
experiments using the same protocol as for CMK cells. 
2.2.4 Thawing frozen cells  
Cryovials containing frozen cells were removed from liquid nitrogen storage and 
immediately placed into a 37 oC water bath. Cells were quickly thawed by gently swirling the 
vial until completely thawed. Before transferring into a laminar flow hood, the outside of 
vials were wiped with 70% ethanol. 1 ml of thawed cells were transferred into a 15 ml falcon 
tube containing pre-warmed complete growth medium. The cell suspension was centrifuged 
at 250 g for 5 minutes to remove media. The cell pellet was resuspended in an appropriate 
volume of growth medium and transferred into culture flask before being placed in a 37 oC/ 5 
% CO2 incubator.  
2.2.5 Cryopreservation of MCF10A and CMK cells  
CMK and MCF10A cells were detached from the flask using the same methods described in 
section 2.2.2 and 2.2.3 respectively and resuspended in the appropriate growth medium. 
Viable cells were counted using trypan blue on the Luna II ™ Automated Cell Counter. Cells 
were then centrifuged at 250 g for 5 minutes and resuspended in appropriate volume of 
freezing medium (7 parts of growth medium, 2 parts of horse serum (MCF10A) or FBS 
(CMK), and 1 part of DMSO) at a concentration of 1x106 cells/ml in each cryogenic storage 
vial. 1ml of resuspended cells was aliquoted into each vial placed on ice. The vials were then 
transferred into de-frost freezing containers (Invitrogen, Life Technology, USA) filled with 
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200 ml of isopropanol and placed at -80 ºC overnight following which they were transferred 
to liquid nitrogen storage.  
2.3  Treatment of CMK & MCF10A cells with Wnt agonists 
2.3.1 CMK Cytospin & Immunofluorescence 
All cells were seeded onto Cellstar® Cell Culture 6-well Plate (suspension) (Greiner Bio-
One). WT and STAG2-/- cells were seeded at 5x105 cells/well. CMK cells were treated with 
CHIR99021 at a final concentration of 10 μm with 2 ml media per well for 4 hours, following 
which cells were trypsinised for cytospin. CHIR99021 was reconstituted in DMSO, hence for 
controls, cells were also treated with an equivalent volume of DMSO for 4 hours.  
2.3.2 MCF10A Immunofluorescence 
MCF10A cells were trypsinised and counted as described in section 2.2.3 for 
immunofluorescence. 6000 cells/well of either WT or STAG2-/- MCF10A cells were seeded 
onto 8 well chamber slides (Nunc® Lab-Tek® Chamber Slide™) The 8 well chamber was 
placed in the incubator (37°C; 5% CO2) overnight to let cells attach. The next day, media 
was replaced with media containing CHIR99021. Treatment with equivalent volume DMSO 
was set up as controls. For these experiments 5 and 10 μm of CHIR99021 was tested and 
cells were fixed for immunofluorescence after 4 and 24 hours.  
2.3.3 Cell fractionation and immunoblotting 
Both CMK and MCF10A cells were seeded at a density of 2.5x106 cells in T75 flasks 
(Greiner Bio-One). Media containing CHIR99021 was then added to the cells. Treatment 
with equivalent volume DMSO was set up as controls. For these experiments 5 and 10 μm of 
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CHIR99021 was tested and cells were subsequently fractionated after 4 (CMK/MCF10A) and 
24 hours (MCF10A only). 
2.3.4 CUT&RUN 
CMK cells were seeded at a density of 2.5x106 in T75 flasks. Media containing CHIR99021 
was then added to the cells. Treatment with equivalent volume DMSO was set up as controls. 
For these experiments 7.5 μm of CHIR99021 was tested and cells were trypsinised and 
collected for experiments after 4 hours.  
2.4  Cytospin   
Treated CMK cells were trypsinised and counted as described in section 2.2.2. Cells were 
resuspended in an appropriate volume of PBS with 1% BSA to attain a concentration of 
100,000 cells/ml. Cells were applied to the SHANDON cytofunnel fitted onto a glass slide 
and spun on the SHANDON Cytospin at 1000 rpm for 3 minutes. Slides were carefully 
removed from cytocentrifuge and visualised under microscope to check for adequate 
dispersion and spacing between cells. Cells were allowed to dry then placed in slide rack. 
2.5  Immunofluorescence analyses of CMK and MCF10A cells 
For CMK cells that were cytospun onto slides, large circles were drawn around the cytospot 
with a hydrophobic pen. For MCF10A, media was removed from the cells treated and 
growing in 8-well chamber slides. Cells were then washed with PBS. The same 
immunofluorescence protocol was followed for both the CMK cytospot and MCF10A cells 
grown in 8 well chamber slides. Both CMK cytospot and MCF10A cells were fixed with 4% 
PFA at room temperature (RT) for 10 min. Cells were washed with PBS, then permeabilized 
with PBS containing 0.1% Triton X for 10 min at room temperature. Cells were then washed 
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with PBS containing 0.5% BSA. Cells were then blocked with PBS containing 2% BSA for 1 
hr at RT.  
The primary antibody (Ab), rabbit anti-total β-catenin (Table 2.5), was diluted 1:1000 in the 
blocking solution. The primary Ab solution was applied to cells and incubated overnight in 
the fridge. The next morning, the cytospots or cells in 8 well chamber were washed twice 
with PBS containing 0.1% Tween, and then once in PBS containing 0.5% BSA .  
Secondary antibody Alexa fluor Goat anti-rabbit-488 was diluted 1:2000 and Hoechst H3342 
(nuclear stain; stock 1mg/ml) (Table 2.5) was diluted 1:1000 in blocking buffer (BSA) and 
this mixture was applied to the cytospot or cells in 8-well chamber and left to incubate for 1 
hr at RT in the dark. After incubation the cells were washed as before with PBS containing 
0.1% Tween, then further washed with just PBS and finally with Milli-Q. Cytospots were 
then mounted using 10 μl of DAKO mounting media and cover slips were placed on each 
spot. Chambers were removed from the 8-well chamber slides, 10 μl of DAKO was applied 
to each chamber and a 24 x 24 coverslip was placed to cover all chambers of slide. Slides 
were left to dry at RT overnight. To check for secondary antibody specificity cytospots or 
cells growing in 8 well chambers were incubated only in secondary antibody and Hoechst 
H33342.  
2.5.1 Confocal Microscopy 
Slides were imaged with 60X oil immersion objective lens on Nikon C2 confocal microscope 
using laser 488 for green (anti-rabbit antibody) and laser 561 for red (mouse-antibody) and 
laser 505 for Hoechst staining. 
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2.5.2 Image Quantification 
To test if the results from immunofluorescence were significant, the nuclear fluorescence was 
quantified. The confocal images were taken and placed into ImageJ, the channels were split 
into the β-catenin and nuclear/Hoechst channels. The Hoechst channel was used to find the 
nuclear periphery and overlaid to the β-catenin channel. Fluorescence of nuclear total β-
catenin was determined relative to the nuclear area. Any nuclei or non-nuclei which had been 
labelled were discounted from the data. The fluorescence of the CHIR99021 treated samples 
was then quantified relative to the untreated (DMSO) samples using Prism. An example 
image of this quantification is shown in Figure 3.2 (A) which shows how ImageJ circles a 
nuclear periphery area (yellow lines) to allow quantification of the nuclear fluorescence. 
Cells such as 39, 129, 46 in (A) Figure 3.2 were discounted from the data as they aren’t round 
nuclei. 
2.6  Cell Fractionation and Immunoblotting 
2.6.1 Cell Fractionation 
Cell Fractionation was performed using the Cell Signalling Technology Cell Fractionation 
Kit (#9038S).  
CMK and MCF10A WT and STAG2-/- mutant cells treated with 5 μm CHIR99021 for 4 
hours were obtained and counted, (MCF10A were treated for both 4 hr and 24 hrs). Each cell 
type was suspended in 500 µl of the appropriate media at a count of 5x106 cells.  
100 µl of cell suspension was aliquoted into a 1.5 ml tube for the whole cell lysate (WCL). 60 
μl of 4X SDS loading buffer (6.0) with β-mercaptoethanol was added for a final volume of 
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160 μl WCL. The tube was sonicated for 15 seconds, at 20% power, 3 times, heated for 5 
minutes at 95 degrees and centrifuged for 3 min at 15,000 g.  
The remaining 400 μl of cell suspension was aliquoted into a 1.5 ml tube and centrifuged for 
5 min at 500 g at 4 ºC, the supernatant was discarded, and the pellet was resuspended in 500 
μl of cytoplasmic isolation buffer (CIB) this was then vortexed for 5 seconds, incubated on 
ice for 5 min, then centrifuged for 5 min at 500 g at room temperature (RT). The supernatant 
was collected into a 1.5 ml tube and labelled the cytoplasmic fraction. The pellet was then re-
suspended in 500 μl of membrane isolation buffer (MIB) and vortexed for 15 sec and 
incubated on ice for 5 min. This was then centrifuged for 5 min at 8,000 g, the supernatant 
was collected and labelled the Membrane and Organelle Fraction. The pellet was resuspended 
in 250 μl of Cytoskeletal/Nuclear Isolation Buffer (CyNIB) and sonicated for 5 sec at 20% 
power, which was repeated 3 times. This fraction was then labelled the cytoskeletal and 
nuclear fraction.  
2.6.2 Immunoblotting 
The BioRad ™ gel casting system was used. 10% sodium dodecylsulfate (SDS) gels were 
created according to the following table, running buffer recipes used for western blotting are 
found in the appendix (6.0). 
Reagent 10% Resolving gel 4% stacking gel 
ddH2O 9.6 ml 5.3 ml 
40% acrylamide 5 ml 2 ml 
1.5M Tris pH8.8 5 ml - 
0.5M Tris pH6.8 - 2.5 ml 
10% SDS 200 μl 100 μl 
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10% APS 200 μl 50 μl 
TEMED 8 μl 10 μl 
Table 2.1 Reagents and volumes used to make 10% resolving and 4% stacking gels 
Glass plates were assembled then the 10% resolving gel was made, poured to cast, and left to 
set for 30 min. Once set the 4% stacking gel was made and cast on top of the 10% gel, a 1.5 
mm comb was added, giving 10 wells per gel. Fractionation samples were diluted 1:4 in SDS 
loading dye with β-mercaptoethanol (6.0) and heated at 95 ºC for 5 min. The samples were 
cooled down to room temperature and loaded on the gel at 20 μl per sample, 5 μl of the 
Odyssey chameleon protein ladder (#928-60000) was loaded alongside the samples. Gels 
were then electrophoresed at 20 milliamps/gel for ~1 hour.   
Semi-dry wet transfer of protein from gel to nitrocellulose membrane was carried out. The 
gels were placed in a sandwich with nitrocellulose paper and placed in the electrophoresis 
tank according to the BioRad manual. Transfer buffer consisted of 1x running buffer and 
20% methanol made up in MilliQ (see appendix (6.0) for buffer recipes). The transfer 
conditions were 100V for 1 hr.  
Once transfer was completed membranes were blocked in Odyssey blocking buffer 1 hr at 
RT. Primary antibodies: rabbit anti total beta catenin (1:1000) and mouse anti-gamma tubulin 
(1:5000) were diluted in Tris-buffered saline (TBS) containing 5% BSA and 0.1% Tween. 
Membranes were incubated in primary antibody solution overnight at 4 ºC.   
The next morning the membranes were washed in the dark as follows: 5 times in TBS+ 
0.01% Tween, then 1x in TBS. Secondary antibodies were diluted in TBS containing 5% 
BSA and 0.1% tween at 1:10000. (IRDye 680-labeled goat-anti-rabbit IgG and IRDye 800-
labeled goat-anti-mouse IgG (LI-COR Biosciences). The secondary antibodies were then 
 28 
placed on the membranes and were incubated in the dark for ~1 hr. Membranes were washed 
as before, placed between 2 filter papers to dry and then scanned on the LI-COR Odyssey® 
scanner. LI-COR Image Studio software was used to analyse and quantify blots.  
2.7  CUT&RUN 
Used the Epicypher CUTANA CUT&RUN kit (#14-1048) and followed the manufacturer’s 
protocol. 0.5 million cells of CMK WT and STAG2-/-, CHIR99021 and DMSO treated cells 
were harvested after 4 hours of drug treatment before use in CUT&RUN.  
Day 1  
2.7.1 ConA Bead Activation 
ConA beads (Concanavalin A) were gently resuspended and 11 µl/sample was transferred to 
a 1.5 ml tube for batch processing. The tube was placed on a 1.5 ml magnetic separation rack 
and left until slurry clears. Supernatant (sup) was removed by pipetting. Immediately 100 
µl/sample cold Bead Activation Buffer was added and pipetted to mix. The tube was placed 
on a magnet until slurry clears and sup was removed. The previous step was repeated for total 
of two washes. Beads were re-suspended in 11 µl/sample cold Bead Activation Buffer and 
activated ConA beads were kept on ice until needed. 
2.7.2 Binding Cells to Activated Beads 
0.5 million CMK WT or STAG2-null mutant cells/sample were harvested by the method 
described in section 2.2.2. Cells were resuspended in PBS transferred to 1.5 ml tube and 
centrifuged  for 3 min at 600 g. The supernatant (sup) was removed by pipetting. The cells 
were resuspended in 100 µl/sample of room-temperature (RT) wash buffer, and spun for 3 
min at 600 x g at RT and supernatant was then removed. This step was repeated for a total of 
two washes. Cells were resuspended in 100 µl/sample in RT Wash Buffer and mixed by 
 29 
pipetting. 100 µl of washed cells/samples were mixed with 10 µl of activated ConA 
beads/sample. This was gently vortexed to mix. The cell/bead slurry was incubated for 10 
min at RT so cells will adsorb to the activated ConA beads. 
2.7.3 Binding of Antibodies 
After incubation the tube(s) were placed on a magnet until slurry clears. Sup was removed by 
pipetting and discarded. 50 µl of cold Antibody Buffer per sample was added quickly, to 
avoid bead drying. This was gently vortexed immediately and thoroughly to an even 
resuspension. 50 µl per experimental sample was transferred into one tube of  8-strip PCR 
tubes. The remaining steps were continued on an 8-strip tubes. 1 μl anti-RAD21, 1 μl anti-
IgG, 1 μl anti-H3K4me3 and 1.5 μl anti-Total β-catenin Antibody (Table 2.5) was added to 
each respective sample and gently vortexed immediately and thoroughly. The 8-strip tube 
was incubated on a nutator overnight at 4ºC with caps slightly elevated at a 30º to 45º angle. 
Day 2 
The tube was placed on a magnet until slurry clears and pipette to remove sup. While beads 
are on magnet, 250 µl cold Digitonin Buffer was added directly onto beads of each sample, 
and then sup was removed by pipetting. The previous step was repeated for total of two 
washes, whilst keeping beads on magnet. Sup was removed and 50 µl cold Digitonin Buffer 
was added to each 8-strip tube, and gently vortexed.  
2.7.4 Binding of pAG-MNase 
2.5 µl CUTANA pAG-MNase (20x stock) was added to each sample, and gently vortexed. 
Samples were incubated for 10 min at RT, and then returned to 8-strip tube magnet, sup was 
then removed by pipetting. While beads were on magnet, 250 µl cold Digitonin Buffer was 
added directly to each sample, and then sup was removed by pipetting. Previous step was 
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repeated for total of two washes, keeping beads on magnet. Sup was removed then 8-strip 
tube was removed from magnet. 50 µl cold Digitonin Buffer was added to each sample, and 
gently vortexed. If beads were clumpy they were dispersed with gentle pipetting with a P200 
pipette.  
2.7.5 Targeted Chromatin Digestion and Release 
8-strip tubes were placed on ice, 1 µl 100 mM CaCl2 was added to samples, and gently 
vortexed. The 8-strip tube was then incubated on nutator with caps slightly elevated for 2 
hours at 4ºC. Once incubation was finished, 33 µl Stop Buffer was added to each sample, and 
gently vortexed to mix. Tubes were then quick-spun in benchtop microfuge. The 8-strip tube 
was placed on a magnet stand until the slurry cleared. The supernatant was then transferred to 
a 1.5 ml tube and then quick spun in a benchtop microfuge.  
2.7.6 DNA purification 
20 ml of 95% ethanol was first added to the DNA wash buffer before first use. 420 µl DNA 
binding buffer was added to each sample and mixed well by vortexing. A DNA clean-up 
column was placed into a DNA collection tube, the samples were then loaded into the column 
and labelled. This was centrifuged for 30 seconds at 16,000 x g, the flow-through was then 
discarded and 200 µl of DNA wash buffer was added to each sample column and centrifuged 
as before. This step was repeated for a total of two washes. After the final wash, the flow-
through was discarded and centrifuged an additional time for 30 sec at 16,000 x g to 
completely dry the column. The column was then transferred to a pre-labelled 1.5 ml 
microfuge tube. DNA was eluted with 12 µl Elution Buffer, once the buffer was added it was 
left to sit and then centrifuged for 1 minute at 16,000 x g at RT. 1 µl per sample was used to 
quantify the CUT&RUN-enriched DNA using the Qubit™ fluorometer as per manufacturer's 
instructions.  
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2.8  CUT&RUN DNA Library Preparation 
I used the NEBNext Ultra™ II DNA Library Preparation Kit (#E7645L) for Illumina and I 
followed the manufactures instruction. NEB Multiplex Oligos (#E7600) for Illumina were 
used for indexing the libraries for next generation sequencing (NGS).  
Required Materials Not Included in Kit  
Freshly prepared 80% ethanol  
Nuclease-free water 
0.1X TE (1mM Tris-HCL, pH 8.0, 0.1mM EDTA 
DNA LoBind Tubes Eppendorf (#022431021) 
NEBNext Singleplex or Multiplex Oligos for Illumina (NEB #E7350, #E7335, #E7500, 
#E6609, #E7710, #E7730 or #E7600) 
Magnetic rack/stand 
PCR machine 
Table 2.2 required materials not included in NEBNext UltraTM II DNA Library Preparation Kit for Illumina Oligo 
#E7600 is shown in bold and underlined as it was used in this protocol. 
The starting material was 5-10 ng of purified CUT&RUN-enriched fragmented DNA. (DNA 
was sheared in 1X TE) 
2.8.1 End repair 
To a sterile nuclease-free tube 3 µl of NEBNext Ultra II End Prep Enzyme Mix, 7 µl of 
NEBNext Ultra II End Prep Reaction Buffer and 50 µl of the fragmented DNA was added to 
give a total volume of 60 µl. This was then pipetted up and down at least 10 times to mix 
thoroughly. The tube was then quick spun to collect all liquid from the sides of the tube. The 
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tube was placed in a thermocycler, with the heated lid set to ≥ 75°C, and the following 
program was run: 30 minutes @ 20°C 30 minutes @ 65°C Hold at 4°C.  
2.8.2 Adaptor Ligation 
The NEBNext Adaptor for Illumina was diluted in Tris/NaCl, pH 7.5-8.0. Input was 100ng-
5ng so a 10-Fold (1:10) dilution was used to give a working adaptor concentration of 1.5 µm. 
The following was added to the mixture in the order stated. End Prep Reaction Mixture from 
previous step (60 µl); NEBNext Adaptor for Illumina 2.5 µl; NEBNext Ultra II Ligation 
Master Mix 30 µl; NEBNext Ligation Enhancer 1 µl. To give a total volume of 93.5 µl. This 
was then pipetted up and down to mix thoroughly and spun in a quick spin benchtop 
microfuge. The tube was then incubated at 20ºC for 25 minutes in a thermocycler with the 
heated lid off. 3uL of USER Enzyme was added to the ligation mixture, this was mixed well 
and incubated at 37ºC for 15 minutes with the heated lid set to 47ºC.  
2.8.3 Clean-up of adaptor-ligated DNA 
The AMPureXP Sample Purification Beads were vortexed to resuspend. 1.1X of resuspended 
beads were added to the H3K4me3 and H3K27ac Adaptor Ligation reactions to retain 
>150bp fragments and 1.75X was added to the β-catenin and IgG samples to retain >50bp 
fragments. This was mixed well by pipetting up and down at least 10 times. The samples 
were incubated on the bench top for at least 5 minutes at room temperature. The tube was 
placed on a magnetic stand to separate the beads from the supernatant. After 5 minutes (or 
when the solution is clear), the tube was carefully removed and supernatant discarded. 
Caution was taken to ensure the beads that contain DNA targets were not disturbed.  
200 μl of freshly prepared 80% ethanol was added each tube while on the magnetic stand. 
This was incubated at room temperature for 30 seconds, and the supernatant was then 
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carefully removed and discarded. This step was repeated once more for a total of two washes. 
The beads were air dried for up to 5 minutes while the tube was on the magnetic stand with 
the lid open. The samples were eluted when the beads were still dark brown and glossy 
looking, but when all visible liquid had evaporated. The tube was then removed from the 
magnetic stand and the DNA targets were eluted from the beads by adding 17 μl of 0.1 X TE 
(#12090015). This was mixed well by pipetting up and down 10 times, or on a vortex mixer, 
then incubated for at least 2 minutes at room temperature. The tube was then placed on the 
magnetic stand again and after 5 minutes (or when the solution is clear) 15 μl of the 
supernatant was then transferred to a new PCR tube. 
2.8.4 PCR enrichment of Adaptor-ligated DNA 
The following components were added to a sterile strip tube in the order stated. Adaptor 
Ligated DNA Fragments (from the previous step) (15 µl); NEBNext Ultra II Q5 Master Mix 
25 µl; i7 Index Primer (5 µl); i5 Index Primer (5 µl); To make up a total volume of 50 µl. The 
index primers used for each sample are listed in table 2.3 below.  
The entire volume was then pipetted up and down at least 10 times to mix thoroughly. A 
quick spin was performed to collect all liquid from the sides of the tube. The tube was placed 
on a thermocycler and PCR amplification was performed using the following PCR cycling 
conditions in Table 2.4 for 14* denaturation and annealing/extension cycles.  
Table 2.3 Barcoding primer table used for PCR enrichment of adaptor-ligated DNA. WTD – WT DMSO; WTC – 
WT CHIR9902;  S2D – STAG2-/- DMSO; S2C – STAG2-/- CHIR99021. b-cat – β-catenin; Ac-H3K27ac; -ve – IgG; +ve 
– H3K4me3. 
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2.8.5 Clean-up of PCR Reaction  
AMPureXP Sample Purification Beads were vortexed to resuspend. 1.1X of resuspended 
beads were added to the H3K4me3 and H3K27ac PCR reaction mix and 1.75X was added to 
the β-catenin and IgG PCR reaction mix. This was then mixed well by pipetting up and down 
at least 10 times. Samples were then incubated on bench top for at least 5 minutes at room 
temperature. The tube was then placed on an appropriate magnetic stand to separate the beads 
from the supernatant. After 5 minutes (or when the solution is clear), the supernatant was 
carefully removed and discarded. 200 μl of freshly prepared 80% ethanol was added to the 
tube while on the magnetic stand and incubated at room temperature for 30 seconds. The 
supernatant was then carefully removed and discarded the supernatant. This step was 
repeated once for a total of two washes. The beads were then air dried for up to 5 minutes 
while the tube was on the magnetic stand with the lid open. The samples were then eluted 
when the beads were still dark brown and glossy looking, but when all visible liquid has 
evaporated. The tube was then removed from the magnetic stand. And the DNA target was 
eluted from the beads by adding 15 μl of 0.1X TE this was mixed well by pipetting up and 
down 10 times and incubated for at least 2 minutes at room temperature. The tube was then 
placed on the magnetic stand, when the solution is clear, 14 μl was transferred to a new PCR 
tube and stored at –20°C. 1 μl was used for quantification on the Qubit (#Q33230). Samples 
Table 2.4 PCR cycling steps and conditions for PCR enrichment of adaptor ligated DNA 
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were then diluted to 10ng/µl and 1μl of this dilution was used to assess the size distribution 
using Agilent Bioanalyzer High Sensitivity DNA chip on the Bioanalyzer (#5067-4626). 
2.9  Sequencing Analyses  
Libraries from the first replicate of CUT&RUN were pooled and sequenced through 
Genohub. Libraries were sequenced as 150 bp paired end reads on HiSeq via Genohub. 
Primary sequencing analyses was carried out by bioinformatician Dr Gregory Gimenez.  In 
brief, Greg aligned it to the human genome version hg19. IgG samples were used to identify 
background and peaks were called using MACS2. ChromHMM chromatin segmentation data 
for K562 was obtained from the ENCODE project (Ernst et al., 2011). Enrichment at 
ChromHMM sites wase determined using using the ‘intersectBED’ function from BED tools 
utilities. To identify unique β-catenin binding sites gained by CHIR99021 treatment and its 
overlap with known TCF-7 (derived from ENCODE - GEO accession number: GSE96429) 
binding sites was determined for each cell type using “intersectBED”. TCF-7 overlapping 
gained β-catenin peaks were annotate to genes using ChIPseeker. This analysis was carried 
out by Dr Jisha Antony.  
I used the ChromHMM enrichment data to determine the distribution of sites versus the total 
peaks for each condition and cell type.  
I used the Integrated genome browser to identify binding sites of the histone marks and β-
catenin in RUNX1, RUNX1T1 and other Wnt target genes. I checked for overlap in binding, 




2.10  Statistical Analysis  
All graphs were generated using Prism, and tables in Microsoft Excel. The difference in 
nuclear β-catenin immunofluorescence staining between WT and STAG2-/- was determined 
using a Student’s t test in Prism.  
2.11  Materials and Antibodies used in experimental methods 
Material Catalogue Number Manufacturer 
Cell Culture and Drug Treatment    
Trypan Blue #T8154 Sigma 
CHIR99021 #HY-10182 MedChem Express 
DMSO  #D2650  Sigma 
DMEM/F-12 #10566016 ThermoFisher Scientific 
RPMI 1640  #A1049101 ThermoFisher Scientific 
Phosphate buffer saline (PBS) #D8537 Sigma 
DPBS #14190144 ThermoFisher Scientific 
Fetal bovine serum (FBS), NZ origin #A3840001 Gibco, Life Technology 
Cholera toxin #9012-63-9 Sigma 
Immunofluorescence   
ProLong™ Gold Antifade Mountant #P36930 Thermofisher 
Triton X-100 #9036-19-5 Sigma 
Hoechst stain (H33342) #875756-97-1 Invitrogen, Life Technology  
Tween 20  #9005-64-5 Sigma 
Nikon C2 confocal microscope N/A Nikon 
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Cell fractionation and 
Immunoblotting  
  
Cell Fractionation Kit #9038S Cell Signalling 
Chameleon® Duo Pre-stained Protein 
Ladder 
#928-60000 LI-COR Biosciences 
Odyssey blocking buffer #927-40100 LI-COR Biosciences 
Bovine serum albumin (BSA) #9048-46-8 Sigma 
Tetramethylethylenediamine (TEMED)  #1610800 BIORAD 
CUT&RUN   
CUTANA CUT&RUN kit #14-1048 Epicypher 
Qubit ™ 1 x dsDNA high sensitivity 
assay kit 
#Q33230 Invitrogen 
Protease inhibitor tablets #11697498001 Roche 
Library Prep   
NEBNext Ultra II DNA Library Prep 
Kit for Illumina L 96 rxns   
#E7645L New England Biolabs 
NEBNext Multiplex Oligos for Illumina 
(Dual Index Primers Set 1)-S 96 rxns 
#E7600S New England Biolabs 
Agilent Bioanalyzer High Sensitivity 
DNA kit 
#5067-4626 Agilent 
AMPure® XP magnetic beads #A63880 Beckman Coulter 
TE Buffer #12090015 ThermoFisher Scientific 
Antibodies (Clone)   
Primary β-Catenin (rabbit) #9562  Cell signalling 
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Primary γ-tubulin (mouse) #5886 Cell signalling 
Primary H3K27ac (rabbit) #8137 Cell signalling 
Primary RAD21 #GTX1066012  Gene Tex 
IRDye 800CW Donkey anti-Goat IgG 
(For beta catenin or for histone 
antibodies) 
#926-32214 LI-COR Biosciences 
IRDye 680CW Goat anti-mouse (For 
gamma tubulin) 
#926-68070 LI-COR Biosciences 
F(ab')2-Goat anti-Rabbit IgG (H+L) 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 488 
#A-11070 Thermofisher 
Miscellaneous   
Ethanol #ET0002025P Scharlab S.L 
Methanol #A412-500 Fisher Chemical 
Tris base  #02-004-508 J.T Baker  
UltraPureTM DNase-RNase free 
distilled water  
#10977015 Invitrogen, Life Technology 








Chapter 3  Results  
Experimental model: I used Down syndrome megakaryoblastic leukaemia CMK cells. These 
cells were previously edited in the Horsfield laboratory to contain a null R614* mutation in 
the STAG2 subunit of cohesin. I used the breast epithelial MCF10A lines for 
immunofluorescence validation experiments. Isogenic parental and cohesin-mutant MCF10A 
lines were also previously established in the Horsfield laboratory. Both cohesin-mutant lines 
were CRISPR-Cas9 edited to contain a deletion mutation in cohesin subunit STAG2. STAG2 
is on the X chromosome and STAG2 mutations are viable due to compensation by the paralog 
STAG1.  
3.1  Wnt agonist CHIR99021 enhances nuclear β-catenin accumulation in CMK 
STAG2-/- cells.  
β-catenin is essential for the transduction of Wnt signalling. In the absence of Wnt signalling, 
the β-catenin destruction complex which consists of several factors including GSK-3 kinase, 
targets β-catenin for degradation. Upon Wnt activation either by ligand binding or GSK-3 
inhibition, β-catenin is stabilized by post translation modification, once stable it can then 
translocate to the nucleus and associate with TCF factors to activate gene transcription. 
Previous work in the Horsfield lab has shown that cohesin-mutant cells are synthetically 
lethal with the Wnt agonist LY2090314 (Chin et al., 2020) and STAG2-/- CMK cells have 
increased sensitivity to WNT3A. When treated with this ligand (WNT3A), the STAG2-/- 
mutant cells show more profound transcriptional changes compared to parental (WT) cells 
(Chin et al., 2020).  The increased sensitivity was attributed largely to enhanced β-catenin 
stabilisation.  
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CHIR99021 is a GSK-3 inhibitor/Wnt activator that is much more affordable and less 
detrimental to cell viability (Naujok et al., 2014), hence was chosen as the Wnt agonist for 
this project. First, I had to validate if Wnt agonist CHIR99021 (Tran & Zheng, 2017) has the 
same effect as WNT3A in the experimental isogenic CMK cells. I used CHIR99021 at 
concentrations between 5-10 µm for this project. This concentration range is similar to that 
previously used in other cell types for Wnt activation (Naujok et al., 2014). 
Immunofluorescence using an antibody that detects total β-catenin levels was performed to 
assess β-catenin accumulation in the nucleus. Parental (WT) and cohesin-mutant (STAG2-/-) 
CMK cells were treated with either 10 μm CHIR99021 or DMSO for 4 hours before being 
cytospun onto slides, fixed and stained with Hoechst H3342 (DNA stain), and a primary 
antibody for total β-catenin. Representative images are shown in Figure 3.1 In the control 
DMSO treated, where Wnt signalling has not been activated, both parental and STAG2-/- 
mutant show low levels of  β-catenin in the nucleus (Figure 3.1 A, B). Then, upon 
CHIR99021 treatment, nuclear β-catenin significantly increases in both WT and STAG2-/- 
mutant cells (Figure 3.1 A, B).  
Figure 3.1 CHIR99021 treatment increases nuclear accumulation of β-catenin in CMK parental (WT) and STAG2-/- 
cells. Shown are confocal immunofluorescence representative images of β-catenin nuclear accumulation following treatment 
with control DMSO or 10 μm CHIR99021 for 4 hours in (A) WT CMK cells and (B) STAG2-/- CMK cells.  Cells were 
stained with Hoechst H33342 (DNA stain) and an antibody against total β-catenin. The merge image shows that β-catenin 
accumulation is largely within the nucleus. Images were taken under 60X oil immersion objective on a Nikon C2 confocal 




Nuclear β-catenin signal in the DMSO and CHIR99021 treated cells were quantified relative 
to nuclear area (refer to methods 2.5.2 for quantification details). Immunofluorescence 
quantification is shown in Figure 3.2 with; (A) an example of image used in the 
quantification process, and (B) The graph generated from quantification of nuclear β-catenin 
in WT and STAG2-/- cells. Prism was used to generate the graph and a Student's t-test was 
used to determine significance. Figure 3.2 B showed that compared to the respective DMSO 
treated condition, there was ~5-fold significant increase (p < 0.0001) in β-catenin 
accumulation in the WT CHIR99021 treated cells and a ~5.5-fold increase in the STAG2-/- 
CHIR99021 treated cells (p < 0.0001). Relative to the WT cells, nuclear β-catenin 
accumulation was ~1.3 fold significantly (p < 0.01) higher in the STAG2-/- cells upon 
CHIR99021 treatment.   
 
Figure 3.2 Quantification of CMK STAG2-/- cells show they have increased nuclear β-catenin upon CHIR99021 
treatment (A) Example of β-catenin quantification image; yellow lines show nuclear periphery, which was determined by 
using the Hoechst H33342 (DNA stain) and ImageJ, the signal inside this periphery was quantified. Image quantification 
analyses was carried out using ImageJ. Non-nuclear regions (examples shown by orange arrows) and overlaying cells or 
doublets were removed (example shown by blue arrow) (B) Relative fluorescence signal of nuclear β-catenin in CMK 
parental (WT) and cohesin-mutant (STAG2-/-) CMK cells was determined relative to the nuclear area using ImageJ. The 
graph represents average relative fluorescence. Significance was determined using Student’s t-test in Prism (63 cells 
analysed for WT DMSO, 62 cells for WT CHIR99021, 86 cells for STAG2-/- DMSO and 60 cells for STAG2-/- CHIR99021: 




Quantification of nuclear β-catenin in parental 
(WT) and cohesin-mutant (STAG2-/-) cells 
 42 
To more specifically quantify the changes in the levels of β-catenin following CHIR99021 
treatment, I decided to carry out cell fractionation and subsequent immunoblotting. Upon 
doing some research into CHIR99021, Morgan et al., 2019 used 5 µm of CHIR99021 with 
very successful results so I decided to use this concentration for this experiment, as it is much 
more sensitive than immunofluorescence. CMK cells were treated with DMSO or 5 µm of 
CHIR99021 for 4 hours and subjected to cell fractionation to individually isolate pools of 
proteins that were membrane bound, cytoplasm associated and nuclear translocated. The 
fractions along with whole cell lysates were then run on 10% SDS gels and subjected to 
immunoblotting (Figure 3.3) using the anti-total β-catenin antibody. Immunoblotting with 
anti-γ-tubulin was used as loading control. The signal for total β-catenin and γ-tubulin was 
quantified using ImageStudioLite™ and relative total β-catenin (β-catenin/γ-tubulin) was 
determined. Graphs in Figure 3.3 are quantification from one fractionation experiment. As 
can be seen from the quantification, compared to DMSO, CHIR99021 treatment increased 
total, membrane-associated, cytoplasm-associated, and nuclear translocated β-catenin in both 
WT and STAG2-/- cells. With the exception of the membrane bound fraction, this 
CHIR99021 mediated increase in β-catenin was more pronounced in the STAG2-/- mutant 
cells compared to WT (Figure 3.3 and 3.4). Compared to WT CHIR99021 treated cells, total 
β-catenin in the whole cell lysate was ~1.75-fold higher in the STAG2-/- CHIR99021 treated 
cells (Figure 3.4).  Within the fractions, STAG2-/- CHIR99021 cells showed ~1.4-fold 
increase in cytoplasmic β-catenin and ~3.25-fold increase in nuclear translocated β-catenin 
compared to WT CHIR99021 treated samples (Figure 3.4). These results indicate that 
CHIR99021 treatment increases nuclear translocation and accumulation of β-catenin in the 




Figure 3.3 An increase in total β-catenin is seen in cohesin-mutant (STAG2-/-) cells and this seems to be attributed to a significant 
increase in the nucleus. CMK parental WT and STAG2-/- cells were treated with DMSO or CHIR99021for 4 hrs and subsequently 
fractionated. (A) Whole cell lysate (B) Membrane fraction (C) Cytoplasmic fraction (D) Nuclear fraction. Immunoblots were stained for total 
β-catenin (green bands) and 𝛾-tubulin (red bands.) Graphs to the right show Quantification of β-catenin bands (green) relative to 𝛾-tubulin 
(red.) Fluorescence intensity was quantified in ImageStudioLite and plotted in Prism.    
 
Figure 3.4 Fold-change in CMK STAG2-/- compared to parental (WT) cells, following CHIR99021 treatment shows 
that the STAG2-/- associated total β-catenin increase is mostly within the nucleus. Fold-change was calculated by dividing 
STAG2-/- CHIR99021treated relative β-catenin fluorescence over WT CHIR99021 treated relative β-catenin. This gave a fold 
change in relative fluorescence for each cell fraction for the CMK cells. Whole cell lysate showed ~1.75-fold change in the 
cohesin mutant, membrane shows ~0.95-fold change, cytoplasm ~1.40-fold change and the nucleus ~3.25-fold change. Graph 
was made in Prism.  
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experiments could not be performed in triplicate. However, the immunofluorescence results 
taken with the immunoblotting results do confirm that CHIR99021 functions as Wnt agonist 
in CMK cells. Further, the increased nuclear β-catenin accumulation seen in STAG2-/- cells is 























3.2  Enhanced β-catenin accumulation upon CHIR99021 treatment is conserved in 
MCF10A STAG2-/- mutants.  
 
I wanted to test if CHIR99021 has the same efficacy as WNT3A in another cell-line to 
further confirm its effect. Isogenic MCF10A cells; either parental (WT) or cohesin-mutant 
(STAG2-/-) were used for immunofluorescence experiments. MCF10A are immortalized, 
normal breast epithelial cells and unlike CMK cells, they are adherent. These cells were 
previously edited in the lab to contain deletion mutation in the STAG2 subunit of cohesin 
(Chin et al., 2020). As I found good nuclear accumulation using 5 µm of CHIR99021 in the 
immunoblot experiment I decided to use this same concentration for the MCF10A 
immunofluorescence, the cells were then imaged at either 4 or 24 hours post-CHIR99021 or 
DMSO treatment.  
 
3.2.1 At baseline MCF10A STAG2-/- cells show greater membrane accumulation 
of β-catenin  
 
Steady state MCF10A cells have a considerable amount of membrane bound β-catenin, where 
it functions to maintain cell-cell adhesion (Shekhar et al., 2008). Consistent with this, as can 
be seen in Figure 3.5 (shown by yellow and grey arrows) membrane bound β-catenin was 
detected in the both WT and STAG2-/- mutant cells at baseline (DMSO treatment, 24 hours). 
Figure 3.5 shows the greater membrane accumulation of β-catenin in WT MCF10A 
compared to STAG2-/- cells at baseline (DMSO treatment, 24 hours). Fig 3.5 also shows that 
the cohesin-mutant DMSO treated cells already have a slight increase in nuclear β-catenin 
accumulation at baseline as seen by the red arrow indicating a nucleus. These results suggest 
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that β-catenin is already stabilized at baseline in the STAG2-/- cells and is consistent with that 
previously observed in by other experiments in the Horsfield lab (Chin et al., 2020).  
  
3.2.2 CHIR99021 treatment enhances nuclear β-catenin accumulation in STAG2-
/- MCF10A cells. 
 
Figure 3.6 shows merges of Hoechst H33342 and total β-catenin at baseline (DMSO) and 
following treatment with 5 µm CHIR99021 at 4 and 24 hours. Similarly to the STAG2-/- 
CMK cells, this figure clearly shows that CHIR99021 treatment of STAG2-/- MCF10A cells 
increases nuclear β-catenin accumulation at both 4- and 24-hours post-treatment. These 
Figure 3.5 MCF10A WT cells show more membrane accumulation of β-catenin than MCF10A STAG2-/- cells at 
baseline. Shown are immunofluorescence images of membrane or slight nuclear accumulation of β-catenin in WT and 
cohesin deficient MCF10A cells treated with DMSO for 24 h. H33342 was used to stain MCF10A nuclei. Merges are an 
overlay of H33342 and total β-catenin. Yellow and grey arrows denote accumulation of β-catenin at the MCF10A 
membrane. Red arrow denotes nucleus of MCF10A cell. Images were taken under 60X oil immersion objective on a 
Nikon C2 confocal microscope using NIS elements software (Nikon). Images were split into respective channels and 
merges were generated on ImageJ. Scale bar = 10 μm.  
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results further confirm that CHIR99021 is as effective as WNT3A in our experiment model 
cell lines. At this point, I could now proceed with confidence to the genomics analyses using 
















Figure 3.6 MCF10A STAG2-/- show more nuclear accumulation of β-catenin than WT cells at upon CHIR99021 
treatment. Immunofluorescence relative images show merges of H33342 and total β-catenin. Cells were treated with 
CHIR99021 5um for either 4 hr or 24 hr and DMSO for 24. Images show increased cytosolic and nuclear accumulation of β-
catenin in STAG2-/- deficient MCF10A cells compared to parental (WT) following treatment with CHIR99021. Images were 
taken under 60X oil immersion objective on a Nikon C2 confocal microscope using NIS elements software (Nikon). Images 
were split into respective channels and merges generated in ImageJ. Scale bar = 10 µm.  
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3.3  Genome-wide profiling of β-catenin and active histone marks (H3K27ac, 
H3K4me3) in isogenic CMK WT and STAG2-/- cells using immunoprecipitation method 
CUT&RUN 
 
3.3.1 Setting up and quality control analyses of CUT&RUN (C&R).  
C&R is a new, efficient nuclease strategy for high-resolution mapping of DNA binding sites 
(Skene & Henikoff, 2017). C&R is similar to chromatin immunoprecipitation (ChIP) but has 
a number of benefits over this technique. C&R was performed using an Epicypher kit (as per 
section 2.7) using antibodies detecting the following marks: H3K27ac; to identify active 
enhancers, H3K4me3; to identify active promoters, IgG; as a negative control to identify non-
specific binding, β-catenin; to identify Wnt target binding sites and RAD21; to identify if 
cohesin localisation is altered. The first step in determining whether CUT&RUN has worked 
is by evaluating the amount of DNA obtained following pull down using the specific 
antibodies. CUT&RUN has a validated protocol for some cell types and histone 
modifications; however, I could not find any literature testing this protocol in CMK cells or 
using a β-catenin antibody. It is worth mentioning that while the project was underway, a new 
CUT&RUN validated RAD21 antibody was published. This antibody was used for replicates 
once it arrived but due to the delay in shipment of this antibody, library preparation from 
these CUT&RUN replicates could not be carried out for timely sequencing. The protocol was 
followed as per the manufacturer’s instructions, and Table 3.1 shows the DNA concentration 
from each of the replicates performed. The table shows that DNA was precipitated from each 
of the samples at a concentration greater than at least 2 ng per sample, which means that as 
long as this wasn’t background DNA, each replicate was successful. I got concentrations for 
IgG ranging from 2-17 ng, for H3K27ac values ranging from 6.006-138.6 ng, for H3K4me3 
values ranging from 8.162 - 26.84 ng, for β-catenin values ranging from 2.046 - 40.26 ng and 
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lastly for RAD21 values ranging from 15.51 – 42 ng. Concentration for the histone marks and 
RAD21 in most replicates was largely higher than β-catenin and IgG, with few exceptions. 
CUT&RUN is well established for the K562 leukaemia cell line, typical CUT&RUN DNA 
total yields from 500k native K562 cells, pre-PCR are as follows: IgG → ~ 3 ng. H3K27me3 
→ ~200 ng. H3K4me3 → ~50 ng. CTCF → ~10 ng. My H3K4me3 DNA yield was ~ 20 ng, 
which is slightly lower than yields seen in K562 cells, my IgG (negative) DNA yield was on 
average < 5 ng which seems very similar to the DNA yield from IgG in K562 cells. Therefore 
I am confident CUT&RUN was successful.  
 
To more specifically determine efficiency I calculated the fold enrichment for the 
CUT&RUN antibodies compared to the respective IgG sample. The fold-enrichment values 
are seen in Table 3.2 below. The data shows there was rather significant DNA enrichment in 
the H3K27ac, H3K4me3 and RAD21 samples, but several of the samples in which the β-
catenin antibody was used, have a fold enrichment below 1, meaning there was less DNA 
Table 3.1 DNA concentrations obtained following CUT&RUN in parental (WT) and STAG2-/- cells histone marks and 
transcription factors are indicated. Boxes show the concentration of DNA generated for each replicate in ng of dsDNA, 1 µl of 
eluted DNA from each sample was used and concentration(ng) was determined using Qubit fluorometric quantification. Negative 
– IgG.  
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precipitated compared to that obtained with IgG (negative). This suggests the β-catenin 
antibody used may not have been the most efficient. This antibody has not been validated for 
use in CUT&RUN experiments before so we were the first to try and perhaps next time a 







Table 3.2 CUT&RUN DNA fold enrichment for H3K27ac, H3K4me3, RAD21 and β-catenin antibodies compared to 
IgG. Fold enrichments represent concentration of C&R DNA for each antibody/cell type/condition relative to the respective 
concentration obtained with IgG for the particular replicate. H3K27ac, H3K4me3 and RAD21 antibodies showed higher 
enrichment than IgG (>1). β-catenin enrichment for most samples was closer or less than IgG, indicating that this antibody is 
less efficient. Replicates 1, 2, 3, 4 are denoted as R1-4. 
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3.3.2 High quality DNA libraries were generated in the sequencing library 
preparation for the H3K27ac and H3K4me3 samples.  
The eluted DNA from each of the C&R samples was used to create DNA libraries for 
sequencing using the NEBNext UltraTM II DNA Library Prep Kit for Illumina (section 2.8). 
After library preparation was complete, the samples were run on the Agilent 2100 high 
sensitivity DNA kit to determine the quality of the libraries. Examples of the Bioanalyzer 
traces are shown in Figure 3.7 below. From both the gel file (A) and electropherograms (B) 
we can see there were high-quality libraries made from the DNA precipitated using the 
H3K27ac and H3K4me3 (positive) antibodies, whereas the β-catenin library was less 
successful – as seen by the less intense bands at ~300bp in lanes 1-4 (A), and the peaks in (B) 
which were similar to the negative controls. Histone nucleosome marks are usually around 
300 bp, hence for purification, a bead ratio of 1.1x was used, this ensures clean-up of library 
preparation associated unligated adaptors. However, for β-catenin, to capture smaller 
fragments, I used a different recommended ratio of 1.75x, as a result unligated adaptors were 
not successfully cleaned and can be seen as 150 bp bands in the bioanalyzer trace. However, 
these were cleaned up by the next generation sequencing (NGS) facility prior to sequencing.  
Figure 3.7 Bioanalyzer traces show the H3K27ac and H3K4me3 (positive) antibodies generated high quality DNA 
libraries. Each of the libraries was run on an Agilent 2100 Bioanalyzer using the high sensitivity DNA kit to determine the 
quality. (A) Example of bioanalyzer trace shown as a gel file.  Showing concentration and sizing of each sample. The sizing 
was determined from the standard ladder loaded in lane 1. (B) Examples bioanalyzer electropherogram for each antibody or IgG 
(negative) are shown. The electropherogram displays a data plot of fragment size (bp) versus fluorescence intensity 
(fluorescence units, FU). Peaks at 35 bp and 10380 bp represent the upper and lower markers. The fragments >150 to 1000 bp 
represent the library. CHIR99021= CHIR99021. 
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3.4  Next generation sequencing analyses of CUT&RUN shows enrichment of β-
catenin, H3K27ac and H3K4me3 (positive) upon CHIR99021 treatment in CMK cells.  
 
The libraries generated from replicate one were sent for next generation sequencing (NGS). 
As CUT&RUN was being trialled for the first time, for timely obtainment of sequencing, 
only one replicate was sent. Libraries were sequenced as 150 bp paired end reads on HiSeq 
via Admera Health, USA. Bioinformatician Dr Gregory Gimenez carried out all major 
genomic analyses. In brief,  Greg aligned raw reads to the human genome version hg19. IgG 
samples were used to identify background and peaks, to identify histone/transcription bound 
sites, peaks were called using MACS2. The graph in Figure 3.8 below shows a footprint 
graph which shows the raw, non-normalized enrichment signal (count) at different regions vs 
size of these regions (fragment length). In both WT and STAG2-/- cells, DMSO or 
CHIR99021 treated, the histone marks show considerable enrichment above IgG. Similar to 
Figure 3.8 Footprint graph shows the CUT&RUN enrichment of H3K37Ac, H3K4me3 and β-catenin in both WT and 
STAG2-/- cells compared to the respective IgG (background) control. Graph shows the enrichment signal (count) at the 
different regions vs size of regions (fragment length; 150 bp- 300 bp).    
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the Bioanalyzer quantification, the signal for β-catenin was close to the IgG suggesting that 
the CUT&RUN with anti-total β-catenin antibody had worked less efficiently. However 
following normalization and peak calling, β-catenin bound sites were detected, and the 
number of bound sites increased with CHIR99021 treatment in both WT and STAG2-/- CMK 
cells (Figure 3.9).  
 
Figure 3.9 shows the total number of H3K27ac, β-catenin and H3K4me3 MACS2 peaks for 
the two different cell types (WT & STAG2-/-) and two different treatments (DMSO & 
CHIR99021). As you can see in Figure 3.9 A the STAG2-/- CHIR99021 treated sample has 
the greatest total number of H3K27ac MACS2 peaks at ~15,000 total peaks. The other three 
samples are considerably lower at ~5000 peaks for each of these, however there does seem to 
be a slight increase in H3K27ac peaks at baseline (DMSO) in the STAG2-/- cells. (B) shows 
the total number of H3K4me3 MACS2 peaks. 3.9 B has the largest scale, ranging up to 
50,000 total peaks. Most of the total peaks are relatively similar for each sample, but there is 
an obvious decrease in total peaks for the WT DMSO sample. 3.9 C shows the total number 
of β-catenin MACS2 peaks, this scale itself only goes up to 5000 total peaks which is 
considerably less than both (A) and (B), however, as you can see, for both the WT and 







Figure 3.9 Number of total MACS2 peaks for H3K27ac, H3K4me3 and β-catenin. Graph shows the number of 
regions (peaks) bound by (A) H3K27ac (B) H3K4me3 and (C) β-catenin in CMK WT and STAG2-/- cell following 
in DMSO or CHIR99021treatment. Peaks from CUT&RUN analyses were called using MACS2. Graphs were 
generated in Prism.  
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3.5  Chromatin state of the sites bound by β-catenin, H3K27ac and H3K4me3 in 
DMSO and CHIR99021 treated WT and STAG2-/- cells  
 
Chromatin-state discovery and genome annotation (ChromHMM) data sets provide 
information about the chromatin state of different regions of the genome (Ernst et al., 2011). 
ChromHMM is good way to see if histone marks and transcription factors are enriched in 
expected regions or not. For particular genomic regions, ChromHMM uses observed histone 
modification marks and insulator factor (CTCF) present at a specific site, to determine its 
chromatin state (Ernst et al., 2011). ChromHMM data indicates active regions (promoters, 
enhancers), inactive regions (repressed, heterochromatin (heterochrome/lo)), Copy number 
variation sites (repetitive/CNV), insulated sites and transcriptional regulatory sites 
(transcription (txn) elongation, weak txn and txn transition). Mapping the CUT&RUN 
obtained peaks to ChromHMM is good way to determine the chromatin state of the sites 
bound by H3K27ac, H3K4me3 and β-catenin. The ChromHMM state for CMK is not 
available, hence the ChromHMM from the well-known K562 leukaemia cell line, which is 
available through ENCODE database, was used. To see where the peaks from Figure 3.9 
mapped to the ChromHMM chromatin segmentation data for K562 leukaemia cells (obtained 
from the ENCODE database) (Ernst et al., 2011) bioinformatician Gregory Gimenez mapped 






Figure 3.10 ChromHMM annotation of H3K27ac at different chromatin states in parental and STAG2-/- DMSO or 
CHIR99021 treated cells. Graph shows percentage of peaks annotated to chromatin state compared to total peaks for H3K37Ac 
marks. Graph was generated in Prism.  
Figure 3.11 ChromHMM annotation of H3K4me3 at different chromatin states in parental and STAG2-/- DMSO or 
CHIR99021 treated cells. Graph shows percentage of peaks annotated to chromatin state compared to total peaks for 
H3K4me3 marks. Graph was generated in Prism.  
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I used the data generated from this to determine the percentage relative to the total peaks for 
each antibody/cell type/treatment. This analysis gave the following graphs (Figure 3.10, 3.11 
and 3.12). H3K27ac and H3K4me3 marks are mostly enriched at active genomic regions 
(Ernst et al., 2011) and consistently ChromHMM mapping showed that the CUT&RUN 
derived H3K27ac and H3K4me3 peaks were associated with active regions. As you can see 
Figures 3.10 & 3.11 shows that in both cell types (WT & STAG2-/-) and both treatments 
(DMSO & CHIR99021) the H3K27ac and H3K4me3 histone modifications were largely 
concentrated at promoters and enhancers. Figure 3.12 shows the distribution of β-catenin 
bound sites in all samples, as you can see, β-catenin seems to localise largely to areas of weak 
transcription, repressed regions and heterochromatin (Heterochrom/lo) regions, with a small 
amount of localisation at both active promoters and weak enhancers. The distribution of β-
catenin at repressed and heterochromatin regions, particularly in CHIR99021 treated cells, is 
unexpected, as Wnt agonism is supposed to target β-catenin to active sites. However the 
Figure 3.12 ChromHMM annotation of β-catenin at different chromatin states in parental and STAG2-/- DMSO or 
CHIR99021 treated cells. Graph shows percentage of peaks annotated to chromatin state compared to total peaks for β-catenin. 
Graph was generated in Prism.  
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ChromHMM data used is from a different cell type and at steady state (without Wnt 
stimulation) hence may not be a true representation of the chromatin state in CMK cells or 
























3.6  Integrated Genome Browser (IGB) analyses at target genes to identify sites 
differentially altered in STAG2-/- cells following Wnt activation.  
 
Due to lack of replicates, statistical differential analyses at the β-catenin, H3K4me3 and 
H3K27ac bound sites (peaks) could not be determined. Therefore, I used the Integrated 
Genome Browser (IGB) and the UCSC Genome Browser to determine whether the signal at 
bound sites is different between cell types and conditions. I examined changes at RUNX1, 
RUNX1T1 and other Wnt target genes. I also checked for overlaps in binding of the two 
histone marks and β-catenin marks. TCF-7 is a transcription factors that associates with 
nuclear β-catenin for signal transduction, hence I extracted existing K562-TCF-7 ChIP-seq 
data (derived from ENCODE - GEO accession number: GSE96429) and determined whether 
the TCF-7 binding sites have altered β-catenin or chromatin marks between conditions. 
 
3.6.1 Chromatin landscape at RUNX1 is altered in STAG2-/- cells upon 
CHIR99021treatment.  
From the MACS2 analyses no β-catenin peaks were determined within the RUNX1 region. 
Figure 3.13 shows the IGB view across the RUNX1 locus. The Y axis shows the enrichment 
signal for each specific antibody, and this was kept the same for each antibody. The genomic 
breakpoints in RUNX1 common to the RUNX1-RUNX1T1 translocation are found in intron 5, 
parallel to a RUNX1 regulatory element, as shown by the dark navy box. As can be seen, no 
strong β-catenin signal was detected in any of the samples at RUNX1. However, peaks were 
detected for H3K27ac and H3K4me3 within RUNX1.  Consistently strong signals could be 
detected for both these marks, and H3K27ac signal shows considerable increases at RUNX1 
in STAG2-/- cells following CHIR99021 treatment. Enrichment of H3K27ac was observed 
particularly at known TCF-7 bound sites or RUNX1 regulatory sites (Marsman et al., 2017; 
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Thomas et al., 2021). In contrast for β-catenin, there is little/no prominent signal seen at the 
RUNX1 P1/P2 promoter, RUNX1 regulatory elements and known TCF-7 sites. Therefore, it 
seems from this experiment using the current antibody, that there is minimal β-catenin 
binding to RUNX1 upon CHIR99021 treatment. This absence of noticeable β-catenin binding 







Figure 3.13 IGB view of CUT&RUN signal at RUNX1. TCF-7 binding sites along RUNX1 are shown as small blue lines at the 
top of the figure. Graphs show binding signal for H3K27ac (orange) H3K4me3 (red) and β-catenin (green) at RUNX1. Below the 
β-catenin signal shown are regions of RUNX1 regulatory elements. RUNX1 P1 and P2 promoters are indicated by the black 
triangles and the RUNX1-RUNX1T1 breakpoint region of RUNX1 is indicated by the navy box. 
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3.6.2 STAG2-/- mutants treated with CHIR99021 show increased active histone 
marks; H3K27ac and H3K4me3 at the P1 & P2 promoter of RUNX1 
The RUNX1 P2 promoter is active in mature haematopoietic cells and the P1 promoter in 
early haematopoietic stem cells (HSCs). P2 can be ectopically induced in STAG2-/- K562 
cells during megakaryocyte differentiation (Antony et al., 2020). Figure 3.14 (A) shows the 
entirety of the RUNX1 gene, TCF-7 binding sites along RUNX1 and the RUNX1 regulatory 
elements and a clear view of the concentration of histone marks H3K27ac (orange) and 
H3K4me3 (red) along the RUNX1 gene. Figure 3.14 (B) shows a magnified view of the P1 
(right) and P2 (left) promoters. As can be seen in the figure titled P1 promoter zoom, there is 
a significant increase in H3K4me3 peak height at the P1  
Figure 3.14 STAG2-/- mutants treated with CHIR99021 show increased active histone marks; H3K27ac and H3K4me3 at the P1 & P2 
promoter of RUNX1 This is an IGB view of RUNX1 promoters P1 and P2. The Y axis is the signal for each antibody: H3K27ac (orange) and 
H3K4me3 (red) and the same axis has been maintained across each cell type/condition. TCF-7 binding sites along RUNX1 are shown as small 
blue lines at the top of the figure. Below the red peaks are regions of RUNX1 regulatory elements seen in blue, below that is the RUNX1 gene 
and chromosomal position. (B) shows a zoom of the P1 and P2 promoters, and these are indicated. The position of the RUNX1 regulatory 
element R1RE13 is also shown by the black triangle.  
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promoter in the STAG2-/- CHIR99021 sample compared to WT at baseline, in this view you 
can also see a slight increase in H3K27ac peaks at the P1 promoter. The P2 promoter zoom 
(B) shows both an increase and spreading of both H3K27ac and H3K4me3 along the RUNX1 
P2 promoter upon CHIR99021 treatment in the cohesin-mutant cells compared to the WT and 
untreated cells. These results suggest that the RUNX1 promoter’s chromatin state is altered 
with Wnt activity, which may then lead to altered RUNX1 transcriptional activity.  
 
 
3.6.3 STAG2-/- mutants treated with CHIR99021 show increased H3K27ac at 
RUNX1 regulatory elements 
Accurate gene expression is crucial for normal development and, in many cases, is achieved 
by the interaction of promoters with cis-regulatory elements (REs). REs, such as enhancers, 
are able to control the expression of genes by long-range chromatin interactions. RUNX1 is 
controlled by regulatory elements (RE’s) which are called R1RE’s (Marsman et al., 2017; 
Thomas et al., 2021) and are bound by several transcription factors, including TCF-7. R1RE1 
is a super enhancer found in the first intron of RUNX1, between the P1 and P2 promoters. 
Previous work in the Horsfield lab has shown that R1RE1 that can make ectopic connections 
upon cohesin loss in K562 cells (unpublished work from the Horsfield laboratory). Figure 
3.15 is a representative image, taken from Thomas et al., 2021, of the RUNX1 gene with 
labelled RUNX1 regulatory elements (R1REs) to give a better understanding of their position. 
R1REs are annotated with their functional validation, ChromHMM characterization, ability 
to produce enhancer RNA (eRNA), SNP status, functional predictions and whether they 
contain mutations present in hematopoietic patients. The key for ChromHMM is in the 
bottom left of the diagram (Thomas et al., 2021). 
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Figure 3.16 shows another magnified view of the RUNX1 gene, but zooming into the RUNX1 
regulatory elements; R1RE1, R1RE15 and R1RE19. As you can see in the magnification of 
the R1RE1 element there is a TCF-7 binding site which aligns with this region. At R1RE1 
there is a strong increase and spreading in H3K27ac peak size in the STAG2-/- CHIR99021 
treated cells compared to WT and DMSO cells. There is also more H3K4me3 in STAG2-/- 
mutant cells at baseline and following CHIR99021 treatment. Interestingly, R1RE13 (Figure 
3.14) is also bound by H3K4me3, STAG2-/- cells appear to have higher H3K4me3 levels 
compared to WT at baseline but levels do not appear to change with CHIR99021 treatment. 
R1RE15 shows a similar pattern of increase, but in acetylation and on a slightly smaller scale. 
The peak circled in black shows the increase in H3K27ac at R1RE15 upon CHIR99021 
treatment. R1RE19 (B) is present at the breakpoint location in RUNX1 involved in the 
RUNX1-RUNX1T1 translocation. H3K27ac was detected in all cells at R1RE19, and the 
Figure 3.15 Schematic overview of human RUNX1 locus and annotations (chromosome 21: 36,148,773-36,872,777). 
Each RE with human origin is annotated with blue circles, REs with mouse origin are annotated with purple circles, grey 
boxes annotate exons. The two RUNX1 promoters are represented by black right angled arrows. R1REs are annotated with 
their functional validation, ChromHMM characterisation, ability to produce eRNA (enhancer RNA), SNP status, functional 
predictions and whether they harbour mutations present in haematopoietic patients. Key for ChromHMM is in the bottom 
left of the diagram (Thomas et al., 2021) 
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signal was slightly stronger in the STAG2-/- CHIR99021 treated cells. Increased H3K27ac at 
RUNX1 regulatory elements – such as R1RE1, R1RE13, R1RE15 and R1RE19 following 
CHIR99021 treatment in cohesin-mutant cells suggests there is altered RUNX1 regulation 




Figure 3.16 STAG2-/- mutants treated with CHIR99021 show increased H3K27ac at RUNX1 regulatory elements. (TCF-7 binding 
sites along RUNX1 are shown as small blue lines at the top of the figure. The Y axis shows binding signal for H3K27ac (orange) 
H3K4me3 (red) at RUNX1. Shown are regions of RUNX1 regulatory elements. The position of the RUNX1 regulatory elements R1RE1 
and R1RE15 (A) are shown by the black triangles and named. The black circle shows the STAG2-/- CHIR99021 H3K27ac peak. R1RE19 




3.7  The RUNX1T1 promoter has increased H3K4me3 binding in cohesin-mutant 
Wnt-agonist treated cells.  
After looking at RUNX1 binding I next looked at its translocation partner; RUNX1T1 to see if 
there were changes in binding of the same histone marks upon CHIR99021 treatment. The 
breakpoints in RUNX1T1 that commonly contribute to the RUNX1-RUNX1T1 translocation 
are located in introns 1b–2  shown by the navy box. Similarly to what was seen in Figure 
3.13, there was little β-catenin binding to RUNX1T1 so these peaks were not included in 
Figure 3.17. Figure 3.17 (A) shows the entirety of the RUNX1T1 gene and 
H3K27ac/H3K4me3 peaks along the gene. Here you can see there is little H3K27ac and 
H3K4me3 binding along the main gene body of RUNX1T1. I observed mainly H3K4me3 
peaks at the promoter and small amount of H3K27ac also. In the WT, CHIR99021 treatment 
increased H3K4me3 at the promoter, however in the STAG2-/- at baseline H3K4me3 was 
higher at the promoter compared to WT. The strength of the H3K4me3 binding didn’t seem 
to be particularly altered by CHIR99021 treatment in STAG2-/- mutant cells. However, the 
CHIR99021 treated STAG2-/- still showed stronger H3K4me3 binding compared to 
Figure 3.17 STAG2-/- mutants treated with CHIR99021 show increased H3K27ac and H3K4me3 at the promoter of 
RUNX1T1. Lines in orange show H3K27ac binding peaks to RUNX1T1, lines in red show H3K4me3 peaks binding to 
RUNX1T1, Below the red peaks is the RUNX1T1 gene and chromosomal position. (A) shows the entire RUNX1T1 gene 
region. (B) shows a zoom of the RUNX1T1 promoter. The AML-RUNX1 breakpoint found largely between exons 1a and 
1b but anywhere from 1b-2 exons is indicated by the navy box. 
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CHIR99021 treated WT. These results show that Wnt activation and cohesin mutation can 
alter the chromatin status of the RUNX1T1 promoter. 
 
3.8  β-catenin binding at TCF-7 sites is altered in cohesin-mutant cells.  
As there was little binding of β-catenin to RUNX1 and RUNX1T1 and no obvious binding to 
Wnt target genes such as Axin-2, MYC and Cyclin D, I felt it was worth looking into unique 
β-catenin binding sites gained by CHIR99021 treatment in both the WT and STAG2-/- cells 
and whether they overlap with the β-catenin associating factor-TCF-7. Unique β-catenin 
binding sites gained by CHIR99021 treatments and their overlap with TCF-7 sites, in each 
cell type was identified using the intersect-bed tool and annotated to genes using ChIPseeker. 
These analyses were carried out by Dr Jisha Antony, I then profiled the data. TCF-7 binding 
sequences were used to validate potential β-catenin binding. Because β-catenin complexes 
with TCF-7, these were likely to be true β-catenin bound sites. 
 
3.8.1 Gene signatures associated with TCF-7/β-catenin bound sites are altered in 
STAG2-/-  compared to WT upon CHIR99021 treatment.  
I used BioVenn to first check if there was any overlap in the genes that were annotated to the 
TCF-7 associated unique β-catenin peaks that were gained in WT or STAG2-/- upon 
CHIR99021 treatment. Figure 3.18 shows a BioVenn diagram – these diagrams allow the 
comparison and visualization of biological lists using area-proportional Venn diagrams. The 
genes in which β-catenin binds to TCF-7 sites in the WT and STAG2-/- cells are listed in the 
respective circles (WT; Cyan & STAG2-/-; Magenta) As you can see, there is no overlap of 
genes between the two CHIR99021 treated samples. Each of the genes for the two samples 
were viewed in IGB to look for peaks, and analysed for potential relationships to cohesin and 
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the Wnt/β-catenin pathway. The two genes chosen for further analysis are shown in bold and 
circled in red.  
 
3.8.2 STAG2-/- CMK cells treated with CHIR99021 show β-catenin binding at a 
strong enhancer/TCF-7 binding site of IL-10.  
Interleukin 10 (IL-10) is an anti-inflammatory cytokine. During infection it inhibits the 
activity of Th1 cells, NK cells, and macrophages, all of which are required for optimal 
pathogen clearance but also contribute to tissue damage (Couper et al., 2008). IL-10 was 
identified as a Wnt stimulated gene in RNA-sequencing analysed carried out by Chin et al., 
2020 in CMK WT and cohesin-mutant cells stimulated with WNT3A.  
Figure 3.19 shows both the IL-10 gene overlaid with the ChromHMM annotation of 
chromatin states. As you can see from the Figure there is a TCF-7 binding site within the 
enhancer region downstream of the IL-10 gene (shown in the blue box at the top of the 
figure). H3K27ac was detected at the same regions in baseline and CHIR99021 treated WT 
cells. In the STAG2-/- mutant cells the signal only became prominent with CHIR99021 
Figure 3.18 There is no overlap of unique gained β-catenin binding sites with TCF-7 between CHIR99021 treated WT 
and STAG2-/- samples. Venn diagram of unique genes with β-catenin and TCF-7 binding in the WT (cyan) and STAG2-/- 
(magenta) samples. Diagram created with BioVenn – which allows the comparison and visualization of biological lists using 
area-proportional Venn diagrams. The gene lists for each of the samples are listed inside the circles. The genes in bold and 
circled are the genes used for further analysis. 
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treatment. It remains to be seen future experiments how alterations in β-catenin binding at 
this region contributes to gene expression. 
 
3.8.3 STAG2-/- CMK cells treated with CHIR99021 show β-catenin binding at an 
active promoter/TCF-7 binding site  of KLHL12 
KLHL12 is a protein that associates with the Cullin-3 ubiquitin ligase complex to negatively 
regulate β-catenin signal transduction (Angers et al., 2006). Figure 3.20 shows the KLHL12 
gene overlaid with ChromHMM annotation of chromatin states. As you can see from the 
Figure there is a TCF-7 binding site within an active promoter (shown by the black arrow at 
the top of the figure.) Based on the MACS2 analyses, a unique β-catenin binding site was 
detected at the KHLHL12 promoter in the STAG2-/- CHIR99021 treated cells. Consistently, 
Figure 3.19 STAG2-/- CMK cells treated with CHIR99021 show β-catenin binding at a strong enhancer/TCF-7 binding site of IL-
10. ChromHMM sites are shown in their associated segment colour to the candidate annotations at the top of the Figure. TCF-7 binding 
sites around IL-10 are shown as small blue dashes at the top of the Figure. The green and orange dashes at the top of the Figure show 
H3K27ac and β-catenin peaks found solely in the STAG2-/- CHIR99021 treated sample. Lines in orange show H3K27ac peaks, lines in 
green show β-catenin peaks, Below the orange peaks is the IL-10 gene and chromosomal position. The position of the strong enhancer 
shown by ChromHMM is shown by the black triangle and named.  
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IGB analyses showed that the β-catenin signal at the promoter was indeed the strongest in the 
CHIR99021 treated STAG2-/- cells. The promoter sites were also bound by H3K4me3 and 
H3K27ac. H3K4me3 levels appeared to quite similar in both cell types. H3K27ac binding 
increased with CHIR99021 treatment only in STAG2-/- cells. These results together suggest 
that the chromatin at KHLH12 is has enhanced activity following Wnt stimulation. KLHL12 
was not identified an a Wnt activated gene in the RNA-sequencing experiment using 
WNT3A performed by Chin et al., 2020. This can suggest either that altered chromatin status 
may not correlate with transcription or that this may be GSK-3 inhibition associated effect. 
Taking all the data into account, these results show that Wnt signalling alters the chromatin 
landscape in cohesin-mutant cells, which gives potential for the enhancement of the RUNX1-
RUNX1T1 translocation.  
Figure 3.20 STAG2-/- CMK cells treated with CHIR99021 show β-catenin binding at an active promoter/TCF-7 binding site of 
KLHL12. ChromHMM sites are shown in their associated segment colour to the candidate annotations at the top of the Figure. TCF-7 
binding sites at KLHL12 are shown as small blue dashes at the top of the Figure. Lines in orange show H3K27ac peaks, lines in green show 
β-catenin peaks, Below the orange peaks is the KLHL12 gene and chromosomal position. The position of the active promoter shown by 
ChromHMM is shown by the black triangle and named. The green and orange dashes at the top of the Figure show H3K27ac and β-catenin 
peaks found solely in the STAG2-/- CHIR99021 treated sample.  
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Chapter 4 Discussion 
4.1  Wnt stimulation enhances nuclear β-catenin accumulation in cohesin-mutant 
cells  
The overall aim of this project was to determine how cohesin mutations increase sensitivity 
to Wnt signalling. I was investigating whether the loss of cohesin would lead to chromatin 
landscape changes and aberrant accumulation of β-catenin at regulatory sites of RUNX1 and 
RUNX1T1 upon Wnt stimulation. I hypothesised that cohesin mutations cooperate with Wnt 
signalling to dysregulate transcriptional changes by altering the chromatin landscape and 
downstream β-catenin-TCF-7 signalling events. 
4.1.1 β-catenin accumulation in DS-AMKL CMK cohesin-mutant cells 
The first aim of this project was to validate whether the Wnt agonist CHIR99021 has the 
same efficacy as WNT3A in CMK leukaemia cells. WNT3A has been successfully used in 
the Horsfield laboratory to assess gene expression changes in CMK cells with STAG2-/- 
mutations through RNA-seq (unpublished data from the Horsfield lab). In a recent paper 
produced by Chin et al., 2020 it was discovered that cohesin mutations are synthetic lethal 
with stimulation of Wnt signalling. This paper used LY2090314, a GSK-3 inhibitor and 
stimulator of the Wnt signalling pathway. However LY2090314 has been shown to be 
somewhat detrimental to cell viability (Kunnimalaiyaan et al., 2018). WNT3A is also rather 
expensive so we wanted to try out another Wnt activator/GSK-3 inhibitor – CHIR99021 
(Tran & Zheng, 2017). My results showed that in CMK cohesin-mutant cells treated with the 
Wnt agonist CHIR99021 there was enhanced nuclear accumulation of β-catenin. This change 
showed that β-catenin is increased by ~29% in the nuclei of CMK-STAG2-/- cells relative to 
parental cells upon CHIR99021 stimulation. This value was very similar to what Chin et al., 
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2020 found for WNT3A stimulation – with a 20% increase in β-catenin in the nuclei of 
CMK-STAG2-/- cells relative to parental cells upon WNT3A stimulation. There were some 
limitations to this experiment however, as CMK cells are non-adherent, Cytospin was used to 
place these cells on slides. The use of Cytospin can mean that cells may sometimes end up on 
top of each other or overlaid in some way as can be seen in Figure 3.1 (C) cell 26.  
To more efficiently confirm CHIR99021’s efficacy, I used cell fractionation and a subsequent 
immunoblot to determine changes in total β-catenin levels. Fig 3.2 and 3.3 show the results 
from the CMK immunoblot, these results were consistent with both the CMK and MCF10A 
immunofluorescence; that there is an increase in β-catenin in STAG2-/- cells upon 
CHIR99021 treatment and that this increase in β-catenin is found within the nucleus. The 
immunoblotting experiment showed a much better upregulation of STAG2-/- nuclear β-
catenin upon CHIR99021 treatment compared to the immunofluorescence. As the 
immunoblot shows increased β-catenin within the nucleus in cohesin-mutants upon Wnt-
agonist treatment, this means there are likely going to be increased transcriptional changes in 
these samples too. It would’ve been beneficial to this experiment if Wnt target genes could 
have been quantified by q-PCR.  
These results altogether showed there is increased nuclear localization of β-catenin in 
STAG2-/-CMK upon CHIR99021 treatment, meaning that CHIR99021 has been validated as 
a Wnt agonist in cohesin-mutant cells. These results were consistent with the findings of Chin 
et al., 2020 and show that Wnt signalling may be a mechanism that contributes to the 
pathogenesis of leukaemia – particularly in DS-AMKL. The enhanced nuclear translocation 
upon CHIR99021 treatment increases the likelihood that there is increased stabilisation of β-
catenin in STAG2-CMK upon Wnt-agonist treatment, which means there is more gene 
dysregulation – as was seen through RNA-seq by Chin et al., 2020. 
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4.1.2 Validation of CHIR99021 in MCF10A cells 
To combat some of these limitations of the CMK immunofluorescence, and to make sure that 
the stabilised b-catenin observed with CHIR99021 treatment was not limited to CMK cells I 
then decided to perform this same immunofluorescence experiment in another cell line; 
MCF10A. MCF10A cells are non-malignant breast epithelial cells with cuboidal epithelial 
morphology (Qu et al., 2015). This, therefore, means they have well defined nuclear and 
cytoplasmic regions. MCF10A cells are also adherent cells so they should show as a single 
cell layer in immunofluorescence, ameliorating this limitation of CMK cells. MCF10A cells 
treated with 5 μm of CHIR99021 mirrored the results found in the CMK cells – a significant 
increase in β-catenin in the nuclei of MCF10A-STAG2-/- cells relative to parental cells upon 
CHIR99021 stimulation. An interesting thing to note about the MCF10A 
immunofluorescence experiments was the accumulation of β-catenin in the membrane of the 
WT cells at baseline which seemed to be lost in the cohesin-mutant (Figure 3.4) In epithelial 
cells (such as MCF10A) cells bind together through the homophilic binding of E-cadherins, 
which form an intracellular molecular complex with several molecules, such as β-catenin and 
actin filaments (Yang & Kim, 2014). It seems that in cohesin-mutant cells there may be loss 
of β-catenin from these cellular junctions as it is transported to the nucleus.  
4.1.3 β-catenin stabilisation 
These results altogether showed there is increased nuclear localization of β-catenin in 
STAG2-/- CMK cells upon CHIR99021 treatment which suggests stabilisation, however, the 
exact mechanism behind this is unclear. One possibility that explains β-catenin stabilisation 
and Wnt hyperactivation in cohesin-mutant cells is linked to energy metabolism. Glycolysis 
in actively proliferating cells of the embryonic tail bud, for example, elevates the intracellular 
pH in developing amniote embryos, causing β-catenin stabilisation (Oginuma et al., 2017; 
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Oginuma et al., 2020). The Warburg effect (Parks et al., 2013; Wang et al., 2016) is a type of 
glycolysis seen in cancer cells, and the mode of glycolysis in developing amniote embryos 
shows many similarities to this. Disturbances in metabolic and oxidative stress in cohesin-
deficient cells, as seen in other studies (Bose et al., 2012; Cukrov et al., 2018) may similarly 
alter β-catenin stability and, as a result, sensitivity to incoming Wnt signals. Further research 
will be needed to determine how β-catenin is stabilized in cohesin-deficient cells and whether 
β-catenin stabilisation is part of a transition to malignancy, and if the associated Wnt 
sensitivity represents a therapeutic opportunity in cohesin-mutant cancers.  
 
4.2  Wnt agonism in cohesin-mutant cells alters the chromatin landscape around 
RUNX1 and RUNX1T1. 
The second and third aims of this project were to use CUT&RUN to determine whether the 
chromatin landscape and β-catenin/TCF-7 binding sites are changed upon Wnt signalling. 
Immediate early transcriptional responses to Wnt signalling were investigated by Chin et al., 
2020 through RNA-sequencing of CMK-STAG2-/- and parental cells at baseline and after 
stimulation with WNT3A for 4 hr. This experiment found that ~76% more genes were 
upregulated in cohesin-mutant cells treated with WNT3A compared to the parental baseline 
control. Expression of RUNX1 or RUNX1T1 was not altered in the parental or STAG2 mutant 
cells following WNT3A stimulation. However, when trying to understand how translocations 
may come about, we don’t necessarily need to look at transcription of translocated genes, 
rather, whether there are changes to the chromatin landscape in these regions, as genomic 
instability drives translocations (Canela et al., 2017). RUNX1 has two promoter regions that 
regulate its expression: the distal P1 and proximal P2. Initiation of the Wnt/β-catenin 
pathway has been shown to produce the longer distal P1-RUNX1 mRNA (Medina et al., 
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2016). Medina et al., 2016 also showed that expression of the RUNX1-P1 promoter is directly 
activated by Wnt/β-catenin signalling which may be important during leukaemogenesis. 
Ugarte et al., 2015 found that stimulating cells with WNT3A – inducing the Wnt/β-catenin 
pathway - increases the expression of RUNX1T1 and RUNX1 genes and also, interestingly, 
brings both the RUNX1T1 and RUNX1 genes into close spacial proximity. Following on from 
this, long-term treatment of human haematopoietic progenitors with WNT3A induced the 
RUNX1-RUNX1T1 translocation. 
4.2.1 The chromatin landscape of RUNX1 and RUNX1T1 
Despite the presence of known TCF-7 sites, no specific β-catenin binding was seen at the 
RUNX1 gene in these experiments, this may have been due to poor antibody quality and/or 
suitability for CUT&RUN. The β-catenin antibody showed very low pull down enrichment 
which I feel was a limitation of this experiment. However, I had examined two histone 
marks: H3K27ac – which is associated with the higher activation of transcription and 
therefore defined as an active enhancer mark (Dong & Weng, 2013), and H3K4me3 – which 
localizes to the 5′ end of active genes and is found associated with the initiated form of RNA 
Pol II – therefore defined as an active or poised promoter mark (Vanzan et al., 2017). As 
stated, RUNX1 is under the control of two different promoters. The distal P1 and proximal 
P2, which give transcripts that differ in the 5’ untranslated regions and N-terminal coding 
sequences (Sroczynska et al., 2009). My results from CUT&RUN show that STAG2- null 
mutation by itself enhances H3K4me3 at both RUNX1 promoters and Wnt activation causes 
increased accumulation of H3K27ac at these sites. This suggests that cohesin mutations and 
Wnt signalling do cooperate to make the chromatin around RUNX1 promoters more active. 
While no changes in total RUNX1 were observed in WNT3A stimulated CMK cells (Chin et 
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al., 2020), it may be possible that the chromatin changes around the RUNX1 promoter relaxes 
chromatin structure which could make it more prone to other genomic changes.  
In AML, RUNX1 is commonly altered through mutations or translocation (Zhang et al., 
2002). While translocation and mutation of RUNX1 are well researched, an equally important 
but less well researched area is how mutations in RUNX1 regulatory elements affect 
expression of the gene. A lot of work in the field of RUNX1/Wnt signalling has looked at the 
activity of promoters and expression of differential RUNX1 mRNA transcripts, but enhancers 
are also extremely important in the context of gene expression. Research on this subject by 
Marsman et al., 2017; Thomas et al., 2021 focused on regulatory elements of RUNX1 and 
how these may contact RUNX1 promoters. They discovered several regulatory elements that 
together form a “chromatin hub” to control RUNX1 expression (Marsman et al., 2017; 
Thomas et al., 2021). My results show that CHIR99021 treatment in cohesin-mutant cells 
increases active histone marks at the RUNX1 regulatory elements, such as R1RE1, R1RE13 
R1RE15 and R1RE19 (Zhang et al., 2002; Thomas et al., 2021), which suggests that these 
sites may become more active upon cohesin mutation and Wnt activation. R1RE1 is a super 
enhancer at +24 that both recruits haematopoietic transcription factors:  SPI1, TAL1, GATA1 
and GATA2 and contacts the P1 and P2 of RUNX1 to increase transcription (Thomas et al., 
2021). Interestingly, R1RE1 was also shown to be able to form long range chromatin 
connections to sites outside the RUNX1 regulatory region (Thomas et al., 2021). R1RE13 
recruits leukaemia associated transcription factors like ERG, GATA2 and RUNX1 while 
R1RE15 has been shown to interact with P2 in K562 and OCI-AML-3 cell lines (Marsman et 
al., 2017; Thomas et al., 2021). R1RE19 is a DNase hypersensitive site (DHS) specific to 
AML samples (Thomas et al., 2021). Together my results suggest that cohesin mutation and 
Wnt signalling may increase the enhancer activity of RUNX1 regulatory elements, which 
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could have implication in transcription factor recruitment and chromatin interactions at 
RUNX1.  
Ugarte et al., 2015 showed that Wnt/β-catenin increases the expression of RUNX1 and of its 
translocation partner RUNX1T1 in human hematopoietic progenitors, likely in RNA-
polymerase-II transcription factories (RNAPII-Ser5). My results from CUT&RUN mirrored 
this finding, that upon Wnt stimulation, both RUNX1 and RUNX1T1 were more active. In 
RUNX1T1 this was shown by increased H3K4me3 at the RUNX1T1 promoter, suggesting that 
RUNX1T1 chromatin is also more sensitive to cohesin mutation and Wnt activation.  
4.2.2 β-catenin binding in Wnt stimulated cohesin-mutant cells 
Since it seemed that the β-catenin pull down was inefficient, β-catenin binding at known 
TCF-7 sites were examined. My results showed that β-catenin binding signatures were very 
different between the WT and STAG2-/- cells upon Wnt stimulation, there was no overlap in 
loci bound by β-catenin, which shows that Wnt signatures and targets in cohesin-mutant cells 
are very different to parental CMK cells. If I had used a more efficacious antibody, an 
overlap would’ve most likely been seen, as when using an inefficient antibody only the 
maximally bound loci will be seen. Nonetheless, these results are similar to what was found 
by Chin et al., 2020 through RNA-seq analysis which showed that upon Wnt stimulation in 
cohesin-mutant cells, a different set of target genes are activated compared to WT cells. Chin 
et al., 2020 found that 402 genes that were not Wnt-responsive in CMK parental cells, 
became Wnt-responsive upon introduction of the STAG2-/- mutation.  Introduction of the 
STAG2-null mutation amplified expression of Wnt-responsive genes and sensitized genes and 
pathways that are not normally Wnt-responsive in CMK. They state that this sensitivity could 
be due at least in part to stabilized β-catenin. Up-regulated genes in STAG2-/- cells should be 
looked into for changes in chromatin landscape.  
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In my results I didn’t see many changes in common Wnt responsive genes, MYC, Axin-2, 
Cyclin D etc. upon CHIR99021 treatment of the STAG2-/- mutant. I did find however β-
catenin binding at the Kelch-like family member 12 (KLHL12) gene. I thought this was an 
interesting gene to include as it definitively shows the Wnt pathway is being activated upon 
CHIR99021 treatment. KLHL12 may act as a substrate adaptor of the Cullin-3 ubiquitin 
ligase complex to promote substrate-specific ubiquitylation, ubiquitylation by this complex 
has been shown to down-regulate the Wnt signalling pathway (Jin et al., 2012). This fits with 
what would be expected upon Wnt activation by CHIR99021, as the pathway is being 
overstimulated, the cell will want to down-regulate the pathway. Thus, β-catenin and TCF-7 
bind to a TCF-7 element at an active promoter of KLHL12 to produce this protein to down-
regulate the Wnt pathway. My results suggest that the chromatin at KHLH12 has enhanced 
activity following Wnt stimulation. However, KLHL12 was not identified an a Wnt activated 
gene in the RNA sequencing experiment using WNT3A (Chin et al., 2020). This can suggest 
either that altered chromatin status may not correlate with transcription or that this may be 
GSK-3 inhibition associated effect. Another interesting gene which binds β-catenin found in 
TCF-7 specific genes in the STAG2-/- mutant was Interleukin-10 (IL-10). IL-10 is not a cell 
type-specific cytokine, but instead is broadly expressed by many monocytes and to a lesser 
extent, lymphocytes. IL-10 downregulates expression of Th1 cytokines and enhances B cell 
survival and proliferation, it is also involved in the JAK-STAT signalling pathway (Saraiva 
& O’Garra, 2010). It is known that that STAG2 loss alters inducible RUNX1 expression in 
megakaryocytes (Antony et al., 2020) and that cohesin is required for inducible enhancer 
activity that underpins inflammatory gene expression (Cuartero et al., 2018). This finding is 
consistent with the role of inflammatory signals and the Wnt signalling pathway. How 
cohesin mutations cooperate with the Wnt signalling pathway and immune regulation is an 
area with little research that could be explored further.   
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4.2.3 Altered chromatin landscape could play a role in the RUNX1-RUNX1 
translocation 
Taking all these results together, this research has shown that in cohesin-mutant cells, upon 
stimulation of Wnt signalling there is an altered chromatin landscape around RUNX1 and its 
translocation partner RUNX1T1, and that this may potentially contribute to the RUNX1-
RUNX1T1 translocation. Currently, there is little known about the chromatin state of 
RUNX1/RUNX1T1 in a cohesin-mutant context and how the common RUNX1-RUNX1T1 
translocation occurs. However we know for translocations to occur, the 
genome/chromosomes have to be in a fragile state. Cohesin-deficient cells have been 
demonstrated to possess genome fragility, as they display compromised nucleolar 
morphology and ribosome biogenesis (Bose et al., 2012; Harris et al., 2014), as well as 
sensitivity to DNA damaging agents (Bailey et al., 2014; Mondal et al., 2019). Canela et al., 
2017 has shown that genome organisation drives chromosome fragility and that this 
organisation is largely driven by cohesin. This study showed that chromosome loop anchors 
bound by CTCF and cohesin are vulnerable to DNA breaks, that these breaks are 
transcription independent, mediated by topoisomerase 2B (TOP2B) and correlate with 
cohesin. In summary, Canela et al., 2017 found that loop anchors serve as fragile sites that 
generate DSBs and chromosomal rearrangements. Taking into consideration previous 
research, my results support my hypothesis and warrant further investigation. I found that the 
chromatin landscape of RUNX1 and RUNX1T1 is altered upon Wnt signalling in cohesin 
mutants, with increased activation at promoters, acetylation at enhancers and TCF-7 sites in 
RUNX1 as well as a more active promoter in RUNX1T1 (Figure 4.1), it is possible that this 
altered chromatin landscape in cohesin mutant cells could contribute to the RUNX1- 
RUNX1T1 translocation (Figure 4.1).  
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4.3  Limitations and Future Directions 
Limitations have been mentioned when discussing experiments above, but some general 
limitations were that many experiments weren’t performed in triplicate, although the results 
are consistent with previous findings. CUT&RUN was performed in triplicate, with 
antibodies for H3K4me3, H3K27ac, β-catenin, IgG and RAD21, but sequencing was only 
performed for one replicate, due to delayed arrival of the RAD21 antibody. For each of the 
histone antibodies there were significant fold enrichments and the DNA obtained was similar 
to the expected yields from 500 k K562 cells. However the β-catenin enrichment was 
significantly lower with many of the samples showing enrichments below zero (Table 3.2). 
However, the fact that the yield of DNA from β-catenin was similar to that of IgG is not 
unusual for transcription factors (Patty & Hainer, 2021). A limitation of the CUT&RUN 
experiment itself was the β-catenin antibody, it didn’t seem to be the most efficacious 
antibody and therefore may not have shown binding to RUNX1 which has been found in 
previous experiments (Medina et al., 2016). It would be a good idea to confirm the effect of 
Figure 4.1 Potential mechanisms of translocation and genomic structure of RUNX1 on chromosome 21 and 
RUNX1T1 on chromosome 8. (Lin et al., 2017). Exons are shown as white/blue boxes. RUNX1 is shown on 
chromosome 21 and RUNX1T1 is shown on chromosome 8. Wnt/β-catenin was shown to induce spatial proximity and 
translocation of RUNX1 and RUNX1T1, Arrows show increase in H3K27ac and H3K4me3 at RUNX1 and RUNX1T1 
which change the chromatin landscape and may contribute to the generation of the RUNX1-RUNX1T1 fusion gene.  
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CHIR99021 by quantification of Wnt target genes through q-PCR alongside the 
immunofluorescence experiments to confirm Wnt target genes were being expressed.  
Thinking about further directions on from this project, CUT&RUN should be repeated using 
a different β-catenin antibody or by using a TCF-7 antibody to identify direct Wnt signalling 
regulated regions. It would be good to see how RAD21 binds, CUT&RUN for RAD21 was 
performed, but due to shipment delays these replicates could not be sequenced in time. 
RAD21 is a subunit that is present in cohesin complexes that contain either STAG1 or 
STAG2. In STAG2 mutants, STAG1-cohesin is the only complex that will be present. Anti-
RAD21 could be used to determine if STAG1 rescues cohesin binding at TCF-7 sites in 
cohesin-STAG2 mutant cells. Following on from this I would investigate why there is 
synthetic lethality with cohesin mutations, exploiting synthetic lethal interactions to target 
recurrent cohesin mutations in cancer, e.g., by inhibiting STAG1, holds the promise for the 
development of selective therapeutics. I would also investigate TOP2B binding, we know 
there is a relationship between cohesin and TOP2B, and that TOP2B is commonly found at 
translocation sites. It would be worth performing C&R looking at TOP2B binding to 
RUNX1/RUNX1T1. TOP2B’s importance in controlling translocations along with cohesin 
seems like a potential mechanism for the RUNX1-RUNX1T1 translocation. I would also like 
to quantify global changes in the RUNX1 P1/P2 promoter activity in cohesin-mutant cells 
upon Wnt stimulation. Lastly, a genome wide profiling of chromatin interaction using HiC 
techniques would be beneficial to see if genome wide chromatin connections are altered in 




4.4  Significance 
My research shows that chromatin state is equally important as transcriptional changes. For 
example the increased activity seen at RUNX1 regulatory elements/enhancers; These changes 
could be contributing to reducing insulation around RUNX1 which could make it susceptible 
to translocation. We know mutations in cohesin are found in pre-leukemic events (Cuartero et 
al., 2019), suggesting that alteration in chromatin state could make it more susceptible to 
occurrence of other mutations. While my research is not immediately translational, 
understanding the mechanisms of this disease is crucial to development of new therapies. 
Perhaps altering enhancer activity using epigenetic mechanisms could be useful as has been 
shown by Calo & Wysocka, 2013. Research into the mechanism of how Wnt signalling co-
operates with cohesin mutations may also provide new insights into the mode of action or 
impact of GSK-3 inhibitors. Etoposide treatment has been shown to induce chromosomal 
translocation (Lovett et al., 2001) - could it be the same for GSK-3 inhibitors which have 
been shown to therapeutic value in some cancers (Manoranjan et al., 2020). Ultimately, 
thoroughly understanding how Wnt signalling cooperates with cohesin-mutations is 
necessary before considering Wnt activation as therapeutic.  
4.5  Concluding remarks 
In summary, I validated the Wnt-agonist CHIR99021 for its efficacy as a Wnt activator in 
both CMK and MCF10A cells. CUT&RUN was performed to identify chromatin landscape 
changes and changes to β-catenin/TCF-7 binding sites. Upon stimulation of Wnt signalling, 
there were changes to both the RUNX1 and RUNX1T1 chromatin landscape in cohesin-
mutant cells which may have implications for the potentiation of the RUNX1-RUNX1T1 
translocation. 
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Taken together, my results support the hypothesis that the loss of cohesin would lead to 
chromatin landscape changes and aberrant accumulation of β-catenin and TCF-7 at regulatory 
sites of RUNX1 and RUNX1T1 upon Wnt stimulation. Future studies are required to see if β-
catenin/TCF-7 binds to regulatory/breakpoint sites of RUNX1/RUNX1T1 and to determine if 
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6  Appendix 
 
Buffers and solutions for SDS-PAGE/Immunoblot 
 
1.5 M Tris, pH 8.8 (stock buffer for separating gels) for 1L  
Tris base 181.65g  
MQ water to 1 L*  
Adjust the pH to 8.8 with concentrated HCl  
 
1.5 M Tris, pH 6.8 (stock buffer for stacking gels)  
Tris base 181.65g  
MQ water to 1 L*  
Adjust the pH to 6.8 with concentrated HCl  
 
10x Tris-Glycine Protein Electrophoresis Buffer (1 L)  
Tris 30.3 g 
Glycine 144 g  
SDS 10 g  
MQ water to 1 L  
 
10x Transfer buffer (4L)  
Tris 121.1 g 
Glycine 576g  
MQ water to 4 L  
 
1x Transfer buffer (1L)  
cold ddH2O 700 ml 
10x Transfer buffer 100 ml 
Methanol 200 ml 
 
4x Reducing Sample Buffer (10mL) (4X loading dye) 
100% glycerol - 4 ml 
0.5 M Tris-HCl pH 6.8 - 4.8 ml 
SDS - 0.8 g 
Bromophenol blue - 4 mg 
β-mercaptoethanol - 0.5 ml  
* Buffers were aliquoted and stored at -20°C  
 
Tris-Buffered Saline (TBS; 10×, pH 7.5) 
Tris 24.2 g  
NaCl 87.7 g   
Combine ingredients in ∼800 ml of H2O.  
Adjust pH to 7.5 with concentrated HCL and bring final volume to 1 L. 
 
1x TBS-Tween (1 L)  
10x TBS - 100 ml  
Tween 20 1 ml 
MQ water to 1 L  
 
